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Multipotent stem/progenitor cells have been identified in nearly all vascularized organs in the 
human body. Our research group recently discovered that human blood vessels harbor various 
stem/progenitor cell populace of mesodermal lineage, exhibiting common multi-lineage 
differentiation capacity and yet distinct cell lineage markers. Specifically, each of the three 
structural layers of blood vessels: intima, media, and adventitia, have been found to respectively 
include one of the three populations of precursor cells: myogenic endothelial cells (MECs), 
pericytes, and adventitial cells (ACs). Our studies have independently characterized each of 
“Three Musketeers” and evaluated their myogenic capacity. Nevertheless, the therapeutic 
potential of pericytes in cardiac repair remains unknown, and whether pericytes natively residing 
in human heart possess similar stem cell characteristics and multipotency has not been 
investigated. Moreover, none of our prior studies has directly compared the regenerative efficacy 
between subpopulations of blood-vessel-derived stem cells (BVSCs), nor did we explore any 
alternative source, other than fresh tissue biopsies, to isolate BVSCs.  
My dissertation study aims to understand the role of subpopulations of BVSCs, pericytes 
in particular, and their relative efficiency in tissue repair/regeneration, with emphases in 
myocardial infarction and skeletal muscle injury. Specifically, my work has three independent 
yet related focuses: (I) to investigate the therapeutic efficacy of human pericyte transplantation 
and associated mechanisms of action in ischemic heart repair; (II) to characterize native human 
heart pericytes and examine whether tissue specificity exists between pericytes of different tissue 
origins; (III) to directly compare the myogenic potential between subpopulations of BVSCs and 
explore alternative source(s) of BVSCs that are more clinically accessible for skeletal muscle 
repair.  
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 Chien-Wen (William) Chen, M.B., M.D., Ph.D. 
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The results of my studies showed that transplantation of human skeletal muscle-derived 
pericytes (SkMPs) repair the infarcted hearts more effectively than control and myoblast groups 
with their multiple restorative effects under hypoxia, including angiogenesis, anti-fibrosis, and 
anti-inflammation. Resident human heart pericytes (HPs) shared common similarity with 
pericytes of other tissues, such as typical pericyte and MSC marker expression, cell growth 
pattern in culture, and certain mesodermal developmental potential. Nevertheless, HPs differ 
from SkMPs in the lack of skeletal myogenic potential and differential angiogenic response 
under hypoxia, tissue-specific phenomena that were not observed previously. Additionally, in 
terms of skeletal myogenesis, MECs demonstrated superior efficiency to pericytes in vitro and in 
vivo. Finally, MECs and pericytes purified from long-term cryopreserved primary human muscle 
culture by cell sorting exhibited similar myogenic potential in vivo to their counterparts isolated 
from fresh biopsies, indicating cryopreservation of unpurified cells may serve as an alternative 
source of therapeutic myogenic precursors.  
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1.0  HUMAN BLOOD-VESSEL-DERIVED STEM CELLS AND THEIR POTENTIAL 
FOR TISSUE REPAIR AND REGENERATION 
1.1 INTRODUCTION 
To date, multipotent adult stem/progenitor cells have been identified in nearly all human organs 
and extensively investigated [1-6]. For example, the human bone marrow (BM) functions as a 
diverse reservoir for several stem/progenitor cell populations, including hematopoietic stem cells 
(HSCs), multipotent mesenchymal stem/stromal cells (MSCs), and endothelial progenitor cells 
(EPCs) [7, 8]. The human skeletal muscle contains committed myogenic precursors, skeletal 
myoblasts, as well as primitive myogenic stem cells, satellite cells [1]. On the other hand, the 
human fat harbors adipose progenitor cells and adipose-derived stem cells (ADSCs) which are 
functionally and phenotypically resembling the BM-MSCs [9, 10].  
However, many of these stem/progenitor cell populations have been identified 
retrospectively in ex vivo tissue and organ cultures, such as multipotent adult progenitor cells 
(MAPCs), mesoangioblasts, and MSCs [10-13]. This obscures the origin and the native identity 
of these stem/progenitor cells in vivo. In order to fully utilize the developmental potentials and 
therapeutic potencies of the adult stem/progenitor cells, it is deemed important to understand 
whether these different populations of adult stem/progenitor cells are developmentally and/or 
hierarchically connected. Due to the phenotypical and functional similarities of several of these 
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stem/progenitor cell populations, we hypothesized the existence of a common source in the 
human body. In this review, we will discuss this newly emerged concept: blood vessel-derived 
mesodermal stem/progenitor cells and their therapeutic applications in the futuristic personalized 
regenerative medicine. 
1.2 STEM/PROGENITOR CELL-BASED THERAPY 
The use of stem/progenitor cells for cell-based therapy is deemed promising owing to not only 
their high proliferative capacity and multi-lineage differentiation potential but also their 
functionality in secretion of trophic molecules and anti-environmental stress to promote cell 
survival. Specifically, adult stem/progenitor cells from an abundant autologous origin have the 
additional advantages over other stem cell types: high availability, no immunogenicity, low 
tumorigeneity, with no associated ethical issues [14]. To efficiently repair/regenerate defective 
organs, the donor stem/progenitor cells are expected to possess desirable therapeutic properties, 
for example, minimal side effects, ability to integrate into host tissue, differentiation into desired 
cell lineages, paracrine effect, immunomodulation, regulation of tissue remodeling, and 
activation of endogenous repair/regeneration mechanisms [15-18]. 
The therapeutic potentials of adult stem/progenitor cells have been extensively 
investigated in the pre-clinical and clinical studies. For instance, MSCs have been widely 
explored in a number of phase I/II and phase III clinical trials for several indications such as 
cardiovascular disease, stroke, multiple sclerosis/amyotrophic lateral sclerosis, Crohn’s disease, 
and osteogenesis imperfecta [19-21]. Many other recent and ongoing human studies have chosen 
bone marrow mononuclear cells (BM-MNCs), skeletal myoblasts, EPCs, or ADSCs as their 
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donor cell populations [16, 22-24]. Unfortunately, in some cases, donor stem/progenitor cells 
initially demonstrated encouraging outcome but later on showed uneven success in clinical trials, 
especially in the treatment of cardiovascular disease [16, 23]. Nevertheless, BM-MSCs, ADSCs, 
and other MSC-like mesodermal stem/progenitor cells still hold great promise for tissue repair 
and regeneration because of their multipotency, autologous availability, immune tolerance and 
regulation as well as robust paracrine secretion of trophic effectors. 
1.3 BLOOD VESSELS AS A SOURCE OF STEM/PROGENITOR CELLS 
The evidence of the vascular wall as a source of stem/progenitor cells has been demonstrated in 
the emerging hematopoietic system in the early development of human embryo and fetus [25]. 
The hematopoietic cells emerge in close vicinity to vascular endothelial cells in both intra- and 
extra-embryonic hematopoiesis. Specifically, a population of angiohematopoietic stem cells 
expressing flk-1 and angiotensin-converting enzyme (ACE) migrates from the para-aortic 
splanchnopleura into the ventral part of the aorta, where they give rise to hemogenic endothelial 
cells and subsequently hematopoietic cells [25]. Furthermore, hematopoietic cells also appear to 
develop from endothelium in the embryonic liver and fetal bone marrow, albeit at a much lower 
frequency. 
The similarity between many human mesodermal stem/progenitor cell populations that 
are retrospectively discovered in tissue/organ cultures has made us hypothesize that there exists a 
common, systemic source of stem/progenitor cells in the adult human body [26]. Blood vessels, 
which consist of three structural layers: tunica intima, tunica media, and tunica adventitia, 
distribute throughout nearly all human organs where adult mesodermal stem/progenitor cells can 
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be identified [27]. Apart from tunica intima, in which the sub-endothelial zone has been 
suggested as one of the sources of endothelial progenitor cells (EPCs), the possibility that other 
structural layers of the blood vessels harbor stem/progenitor cells was recently demonstrated in 
tunicae media and adventitia [26, 28, 29].  
Perivascular cells, often known as vascular mural cells, are the cells that surround tunica 
intima of the blood vessels and constitute a major component of the vascular wall [27, 30]. 
Microvascular pericytes, though similar but distinct from vascular smooth muscle cells, closely 
encircle endothelial cells in capillaries and microvessels (arterioles and venules) in most human 
tissues [30-32]. Pericytes are commonly regarded as a structural element of blood vessels that 
regulate vascular contractility and support the stability of blood vessels [33-35]. Intimate 
interactions between pericytes and endothelial cells tightly relates to the vascular growth, 
maturation and remodeling [30, 34-36]. In addition, pericytes have been implicated in a number 
of pathological conditions, making them the potential targets for therapeutic interventions [36, 
37]. 
Historically, the outmost layer of arteries and veins, the tunica adventitia, has been 
considered as a mere structural bystander constituted by collagen and fibroblasts. A number of 
recent findings have led to the re-evaluation of the active role of tunica adventitia in cell 
trafficking, immune response mediation, and vascular remodeling [38]. The importance of the 
tunica adventitia in regenerative vascular medicine is highlighted by the numerous reports 
describing the presence of multipotent progenitors within the wall of arteries and veins [29, 39-
42]. In a vascular remodeling setting following an injury, it has been shown that adventitial cells 
(ACs) start a process of proliferation, migration into the tunicae media and intima, and 
differentiation into smooth muscle cells [41, 43, 44]. 
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We have previously investigated whether the blood vessels contribute to stem/progenitor 
cell lineages other than hematopoietic cells. Through immunohistochemistry and flow cytometry 
analyses, we documented evidences showing the existence of rare subsets of human blood vessel 
derived stem cells (hBVSCs) in multiple human tissues, including skeletal muscle, fat, and 
placenta.  
1.4 THE THREE MUSKETEERS OF BLOOD VESSEL WALLS: MYOGENIC 
ENDOTHELIAL CELLS, PERICYTES, AND ADVENTITIAL CELLS  
We and other laboratories recently reported the existence of three distinct subpopulations of 
mesodermal precursors within the human blood vessel walls through anatomic and molecular 
identifications. At least one precursor subset, i.e. myogenic endothelial cells (MECs), pericytes, 
and adventitial cells (ACs) (Figure 1), was contained in each of the three tunicae of blood vessels: 
intima, media, and adventitia, respectively [26, 40, 45-47].  
 
Figure 1: Morphology of hBVSCs 
Distinct morphology of the three purified subpopulations of human blood vessel derived stem cells (hBVSCs) in 
culture. From left to right: myogenic endothelial cell (MEC), pericyte, and adventitial cell (AC) (100X). 
Myogenic endothelial cells (MECs), which suggest a developmental relationship between 
endothelial and myogenic cells, have been identified within the vasculatures of human skeletal 
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muscle at a very low frequency (<0.5%) [45]. MECs uniquely co-expressed myogenic (CD56) 
and endothelial cell markers (CD34 and CD144) and were identified by immunohistochemistry 
and flow cytometry. Using fluorescent-activated cell sorting (FACS), we were able to purify 
these cells to homogeny [45]. MECs (CD56+CD34+CD144+CD45–) proliferate long term, 
retain a normal karyotype, survive better under oxidative stress than CD56+ myogenic cells, and 
are not tumorigenic [45]. Cultured MECs displayed mesenchymal developmental capacities, 
including myogenesis, osteogenesis, chondrogenesis, and adipogenesis, under appropriate 
inductive conditions in vitro [45]. Their stem cell characteristics were further confirmed by the 
expression of classic MSC markers and the mesodermal differentiations in culture from clonally 
derived MECs (Zheng et al., in revision). However, it is not clear yet whether MECs give rise to 
authentic MSCs in culture. Based on the phenotypic and functional similarities between MECs 
and the previously reported murine muscle derived stem cells (mMDSCs), we believe that MECs 
represent the human counterpart of mMDSCs (Zheng et al., in revision). In addition to MECs, 
which are primarily located in the intimal compartment of the blood vessels within human 
skeletal muscle, other distinct subsets of multipotent stem/progenitor cells were recently found in 
the perivascular compartment of the vasculature (tunicae media and adventitia), not only within 
the skeletal muscle but throughout the human body [26, 40, 46, 47].  
Though microvascular pericytes have long been considered to possess mesenchymal 
plasticity, the lack of a proper purification method undermined the characterization of this 
potential precursor population [48-50]. Recently our group identified the native expression of 
classic MSC markers by microvascular pericytes and further discovered a collection of cell 
surface markers, i.e. CD146+CD34−CD45−CD56−, that enabled us to prospectively isolate 
homogenous pericyte populations by FACS from multiple human organs [26]. Purified pericytes 
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proliferate long term and express CD146, NG2, PDGFR-β, alkaline phosphatase (ALP), and α-
smooth muscle actin (α-SMA), with the absence of endothelial cell markers, including von 
Willebrand factor (vWF), CD31, CD34, and CD144 [26, 46]. These cells can be efficiently 
expanded in vitro and demonstrate robust mesodermal developmental potentials, at the clonal 
level, by differentiating into osteogenic, chondrogenic, adipogenic, and myogenic lineages under 
suitable inductive conditions in vitro [26]. The MSC characteristics of these 
CD146+CD34−CD45−CD56− pericytes can be maintained for the long term in culture. Their 
myogenic and osteogenic capacities were further displayed by transplantation into the muscle 
pocket of immunodeficient mice. To date, no tumorigenicity of pericytes has been reported [26, 
46]. We hypothesized that these cells are one of the developmental origins of MSCs [26]. 
In the past, fibroblasts that are capable of differentiating into myofibroblasts/smooth 
muscle cells (SMCs) following vascular injury have been regarded as the primary cellular 
component of the tunica adventitia [38, 51]. Recent studies have gradually uncovered the true 
identity of the cells residing in this outmost layer of the blood vessels [42]. Cells located at the 
interface between the tunica adventitia and media, the so-called “vasculogenic zone”, have been 
identified as CD34+CD31- and described as progenitors endowed with the ability to differentiate 
into endothelial cells and participate in the blood vessel formation as well as the pathogenesis of 
atherosclerosis [29, 41, 51]. The concept that the tunica adventitia functions as a reservoir for 
stem/progenitor cells is highlighted by a recent study in which a population of CD34+CD31- 
progenitors residing in human saphenous vein was described [40]. These cells were localized in 
the tunica adventitia in situ and could be isolated and expanded at the clonal level in vitro. Our 
study also showed the stem cell characteristics of a CD34+CD31-CD146- non-pericyte 
perivascular cell population in the vasculature of human adipose and other tissues [47]. The 
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FACS-purified CD34+CD31-CD146- population exhibited the phenotype and developmental 
potentials of MSCs. Furthermore, immunohistochemistry revealed that CD34+CD31-CD146- 
cells reside in tunica adventitia of blood vessels in multiple human organs and similar to 
pericytes, natively express classic MSC surface markers.  
1.4.1 Myogenic endothelial cells for skeletal muscle regeneration and cardiac repair   
The therapeutic potential of myogenic endothelial cells (MECs) was first tested in the severe 
combined immunodeficiency (SCID) mouse model of cardiotoxin-injured skeletal muscle [45]. 
MECs (CD56+CD34+CD144+CD45–) isolated from fresh human muscle biopsies were shown 
to regenerate skeletal myofibers more effectively than skeletal myoblasts (SkMs, 
CD56+/CD34−/CD144−/CD45−), endothelial cells (ECs, CD34+/CD144+/CD56−/CD45−), and 
unpurified primary muscle cells, with or without in vitro expansion. Injection of MECs into 
skeletal muscle of mdx/SCID mice, a disease model of Duchenne muscular dystrophy (DMD), 
also displayed an efficient regeneration of human skeletal myofibers, indicated by positive 
staining of both dystrophin and human lamin A/C [45]. Furthermore, after expansion in culture, 
clonal MECs exhibited robust chondrogenesis and osteogenesis in vivo after implantation into 
the hind-limb muscle pocket of SCID mice (Zheng et al., submitted). These results suggest the 
feasibility of utilizing MECs to treat various musculoskeletal disorders. 
The application of MECs in the cardiovascular disease was examined in an immune-
deficient mouse model of acute myocardial infarction (AMI) [52]. Myocardial infarction was 
induced in SCID-non-obese diabetic (NOD/SCID) mice by ligation of left anterior descending 
coronary artery (LAD), and cells were immediately injected into the ischemic myocardium. 
Cardiac function was assessed by echocardiography. The results demonstrated a significant 
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improvement in cardiac contractility after intramyocardial injection of MECs when compared 
with injections of SkMs and ECs [52]. Transplanted MECs not only displayed robust 
engraftment within the infarcted myocardium but also stimulated angiogenesis, attenuated scar 
tissue formation, and promoted proliferation and survival of endogenous cardiomyocytes more 
effectively than the other two cell types [52]. This is presumably attributed to higher secretion of 
vascular endothelial growth factor (VEGF), a potent angiogenic factor, by MECs under hypoxia. 
Similar to mMDSCs, MECs regenerated significantly more fast-skeletal MHC-positive 
myofibers in the ischemic heart. A minor fraction of engrafted MECs differentiated into and/or 
fused with cardiomyocytes by expressing cardiomyocyte markers, cardiac troponin-T and –I [52]. 
These findings suggest that MECs represent a promising stem cell subset within human skeletal 
muscle, an accessible autologous tissue source, for cardiac repair and regeneration. 
1.4.2 Pericytes for tissue repair and regeneration 
The application of pericytes in regenerative medicine was first examined in SCID mouse models 
of injured and dystrophic skeletal muscle [26]. Microvascular pericytes freshly sorted by FACS 
from human skeletal muscle were injected into the hind-limb muscles of SCID-non-obese 
diabetic (NOD/SCID) mice that had been injured by intramuscular injection of cardiotoxin. The 
presence of regenerating human spectrin-positive myofibers was detected by 
immunohistochemistry and confirmed by fluorescence in situ hybridization of central human 
nuclei [26]. Quantification showed that freshly sorted or long-term cultured pericytes produced 
more human myofibers than purified SkMs and unpurified muscle cells, ruling out the possibility 
that the myogenic potential observed in pericytes resulted from a consequence of the 
contamination by myoblasts. Most importantly, this myogenic potential can be generalized to 
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pericytes residing in non-muscle tissues. Placenta-, white adipose tissue- and pancreas-derived 
pericytes also exhibited high myogenic potential in culture and in vivo, yielding human 
dystrophin- or spectrin-positive myofibers upon transplanted into mdx/SCID or cardiotoxin-
treated NOD/SCID mouse muscles [26]. Dellavalle et al. also showed that pericytes sorted from 
healthy and dystrophic human skeletal muscles by ALP expression regenerate human myofibers 
in muscles of dystrophic immunodeficient mice [46]. Very recently, the same group 
demonstrated that pericytes residing in the postnatal skeletal muscle natively participate in the 
skeletal myofiber development and the satellite cell compartment and further contribute to the 
regeneration of injured/dystrophic skeletal muscle, using a transgenic label of inducible Alkaline 
Phosphatase CreERT2 [53]. These results indicate that pericytes play a role in muscle ontogeny 
and are endowed with robust myogenic potential that can be applied to skeletal muscle repair and 
regeneration.  
With their inherent functions in the vascular physiology, pericytes seem to match the 
criteria of the ideal donor cell population for cardiovascular repair. Moreover, a human pericyte-
based small-diameter vascular graft has been successfully engineered with high patency after 
long-term transplantation [54]. I investigated the hypothesis that transplantation of cultured 
pericytes benefits the ischemic heart, which is documented in detail in chapter 3 of this 
dissertation [55]. Briefly, long-term cultured human muscle pericytes were injected into acutely 
infarcted hearts of NOD/SCID mice. Echocardiography revealed a significant improvement of 
cardiac function in pericyte-injected hearts. Pericytes exhibited cardio-protective effects such as 
promotion of angiogenesis, reduction of scar formation, and inhibition of chronic inflammation 
(Chen et al. submitted).  These data suggest that pericytes serve as a promising donor cell source 
for stem cell-based cardiovascular therapy. 
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1.4.3 Adventitial cells exhibit multi-lineage potential for blood vessel and tissue 
regeneration 
The potential application of adventitial cells (ACs) in the clinical settings has thus far been 
focused on the cardiovascular repair and regeneration. Campagnolo et al. recently demonstrated 
that CD34+CD31- ACs interact with endothelial cells and promote the formation and 
stabilization of the capillary-like structures [40]. Most importantly, injection of adventitial in a 
hind-limb ischemia mouse model cells showed a significant pro-angiogenic effect as 
demonstrated by a full blood flow recovery as early as 7 days post-injection, indicating the 
therapeutic potential of ACs in angiogenesis/vasculogenesis [40]. Very recently, Katare et al. 
further reported that transplantation of ACs improves the repair of infarcted hearts through 
angiogenesis involving microRNA-132 [56]. Together these data indicate the therapeutic 
potential of ACs in ischemic tissue repair. Interestingly, the use of ACs derived from the 
umbilical artery, in conjunction with SMCs of the same source, in tissue-engineered small-
caliber vessel constructs resulted in superior mechanical properties than the same constructs 
using cells derived from the umbilical vein, suggesting that ACs and SMCs originating from 
different sources may lead to distinct tissue characteristics in regenerative medicine [57]. 
The application of ACs is not limited to post-natal angiogenesis/vasculogenesis or 
cardiovascular repair. Though the myogenic potential of ACs remains to be determined, we and 
other authors have demonstrated that adventitial cells, regardless of their tissue of origin, display 
features typical of MSCs [40, 42, 47]. The ability of ACs to differentiate into major mesodermal 
cell lineages, including osteogenesis and chondrogenesis, suggests a likely contribution of these 
cells to the formation/regeneration of surrounding mesenchymal tissues after injury and further 
expands the potential clinical applications of this unique hBVSC subset into the field of 
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musculoskeletal diseases [47]. Altogether, these reports suggest that rather than a passive 
constituent of the vascular wall, the adventitia is a dynamic reservoir of stem/progenitor cells 
that participate in vascular remodeling and regeneration of surrounding tissues. 
1.5 ONTOGENY AND HETEROGENEITY, INNATE FACTORS AFFECTING THE 
THERAPEUTIC POTENCY OF STEM/PROGENITOR CELLS? 
MSCs represent a highly heterogeneous population of widely studied but poorly defined 
multipotent stem/progenitor cells [58]. Indeed, Guilak et al. have shown that only 52% of the 
clones obtained from cultured ADSCs retain the ability to differentiate into two or more 
mesodermal cell lineages [59]. The presence of subsets of cells with limited or no differentiation 
potential within the conventional stromal cultures may therefore hamper the clinical efficacy of 
these promising stem/progenitor cells. This raised the possibility that clinical trials based on the 
transplantations of the total SVF or unfractionated MNCs often showed uneven success because 
of the variable frequency of progenitors within the total stroma [16, 23]. Additionally, 
mesenchymal progenitors have mostly been selected by their plastic adherence and expanded 
long-term in culture with reagents originated from animals, which ultimately limits their clinical 
use due to FDA regulations. 
The identification of pericytes as, at least in part, the ancestors of MSCs has represented a 
breakthrough in the search for the true identity of MSCs [26]. Though this has raised the 
possibility that most MSCs, if not all, are derived from pericytes, other subsets of 
stem/progenitor cells residing in the blood vessel walls may constitute part of the MSC entity as 
described above [60]. The question of whether all MSCs originate from microvascular pericytes 
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is partially answered by Tormin et al., who reported that, in bone marrow, MSCs can be derived 
not only from the subendothelial sinusoidal CD146+ cells, as previously demonstrated by 
Sacchetti et al., but also from the bone-lining CD146- cells [61, 62]. Furthermore, using the 
genetic lineage tracing, Feng et al. recently reported MSCs from both pericyte and non-pericyte 
origins differentiate into odontoblasts and participate in tooth growth and repair in mice, 
suggesting that the pericyte contribution to MSCs may vary in different tissues and possibly 
depend on the density of the local vascularity [63].  
Another good example that different subsets of stem/progenitor cells contributing to the 
MSC entity is from the observation of the concurrent presence of two distinct subpopulations of 
perivascular multipotent progenitor cells, namely CD34-CD31-CD146+ microvascular pericytes 
and CD34+CD31-CD146- adventitial cells, in the adipose tissue [39, 47]. These two 
subpopulations of hBVSCs share in situ and in vitro expression of typical MSC surface markers, 
CD44, CD73, CD90 and CD105, but they are phenotypically and anatomically distinct [39, 47]. 
Pericytes are indeed defined as CD45-CD34-CD31-CD146+ cells tightly surrounding 
microvessels, whereas CD45-CD34+CD31-CD146- adventitial cells are located in the outmost 
layer of larger blood vessels in the human adipose, a literally unlimited tissue source. Both 
subpopulations of cells are endowed with multi-lineage mesenchymal differentiation capacity at 
the clonal level and represent ideal candidates for the treatment of musculoskeletal and vascular 
diseases [39, 40, 64]. Above all, both subpopulations are abundant in lipoaspirate; and with the 
definitive phenotypes of each hBVSC fraction, we can readily enrich both fractions by cell 
sorting in order to improve their therapeutic efficiency and safety [47]. Table 1 summarizes the 
basic characteristics and potential clinical applications of hBVSC subpopulations and BM-MSCs.  
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Table 1: Comparison of hBVSC subpopulations and bone marrow MSCs 
 
MEC: myogenic endothelial cell; AC: adventitial cell; BM-MSC: bone marrow mesenchymal stem/stromal cells; 
N/A: not available; ND: not determined. 
Nevertheless, while all, or at least part of, the three hBVSC subpopulations contributing 
to the MSC entity in culture is gradually becoming an accepted notion, whether the multi-lineage 
 MEC Pericyte AC BM-MSC 
Native location Intima Media Adventitia Bone marrow 
Surface marker profile 
for cell sorting 
CD34+ 
CD45- 
CD56+ 
CD144+ 
CD34- 
CD45- 
CD56- 
CD146+ 
CD31- 
CD34+ 
CD45- 
CD146- 
N/A 
Classic MSC marker 
expression in culture 
CD29+ 
CD44+ 
CD90+ 
CD105+ 
CD44+ 
CD73+ 
CD90+ 
CD105+ 
CD44+ 
CD73+ 
CD90+ 
CD105+ 
CD29+ 
CD44+ 
CD73+ 
CD90+ 
CD105+ 
Differentiation in vitro Osteogenic (+) 
Chondrogenic (+) 
Adipogenic (ND) 
Myogenic (+) 
Osteogenic (+) 
Chondrogenic(+) 
Adipogenic (+) 
Myogenic (+) 
Osteogenic (+) 
Chondrogenic (+) 
Adipogenic (+) 
Myogenic (ND) 
Osteogenic (+) 
Chondrogenic (+) 
Adipogenic (+) 
Myogenic (+) 
Differentiation in vivo Myogenesis 
 
Myogenesis 
   Osteogenesis 
Vasculogenesis Osteogenesis 
Chondrogenesis 
Adipogenesis 
Myogenesis 
Cardiomyogenesis 
Vasculogenesis 
Potential Clinical 
Application 
Skeletal muscle 
repair/regeneration; 
Cardiac repair 
Skeletal muscle 
repair/regeneration; 
Vascular repair 
/regeneration 
Vascular repair 
/regeneration; 
Cardiac repair 
Bone repair; 
Cartilage repair;  
Tendon/ligament 
repair; Skeletal 
muscle repair; 
Vascular repair; 
Cardiac repair;  
Wound healing;  
Immunoregulation 
 15 
potentials are natively present within hBVSC subsets and subsequently responsive to 
pathological stimulations in vivo remain to be investigated (Figure 2). Ultimately, the current 
therapeutic strategy based on the transplantation of unfractionated stromal cells may in the near 
future be replaced by the purification, combination, and direct re-infusion of the distinct subsets 
of hBVSCs, devoid of cells with none or a restricted regenerative potential.  
1.6 CONCLUSION 
In this chapter, I introduced the newly emerged concept of blood vessels as a systemic source of 
adult stem/progenitor cells. Three subpopulations of hBVSCs, i.e. MECs, pericytes, and ACs, 
have been respectively isolated from different layers of the blood vessels and examined in detail 
for their developmental capacities and therapeutic potentials in tissue repair and regeneration. 
Besides the fresh tissue biopsy, the cryogenically banked primary human skeletal muscle culture 
was shown to be an alternative source of myogenic subsets of hBVSCs, shedding new lights on 
the future of the personalized regenerative medicine. Finally, the identification of the precise 
phenotypes of distinct hBVSC subpopulations represents not only an important milestone for 
understanding the nature and origin of MSCs but also a crucial step toward the improvement of 
stem/progenitor cell based therapies. 
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Figure 2: Schematic depiction of hBVSCs at the origin of mesenchymal stem/stromal cells (MSCs) 
(A) hBVSCs, including myogenic endothelial cells (MECs, red), pericytes (green) and adventitial cells (AC, blue), 
are dissociated from fresh muscle biopsy and separated from endothelial cells (yellow) and other cell types. (B) 
Dissociated cells are purified to homogeneity by fluorescence-activated cell sorting (FACS), and newly sorted 
MECs, pericytes, and ACs already exhibit multi-lineage developmental potentials. (C) FACS-purified pericytes, 
ACs, and possibly MECs give rise to authentic MSCs in long-term culture. (D) Nevertheless, whether native 
hBVSCs serve as a source of MSCs in situ and participate in tissue repair and regeneration remains an open question. 
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2.0  MESODERMAL PRECURSOR CELLS FOR CARDIOVASCULAR REPAIR 
AND ASSOCIATED MECHANISMS 
2.1 INTRODUCTION  
In spite of recent advances in surgical and therapeutic interventions, cardiovascular diseases 
(CVD) remain the leading cause of death in the United States to date, accounting for 1 of every 
2.9 deaths [65]. Coronary heart disease (CHD), affecting nearly 18 million American people, is 
caused by conditions that interfere with the coronary blood supply to the myocardium, such as 
atherosclerosis and thromboemboli [66]. Prolonged ischemia results in ischemic cardiomyopathy 
and myocardial infarction (MI), which in turn lead to heart failure (HF) or death due to a very 
limited capacity of the adult human heart to repair/regenerate its irreversibly damaged cardiac 
muscle [66]. Conventional therapeutic gold standards for patients who require treatments beyond 
interventional therapies include coronary artery bypass grafts (CABG) and heart transplantation, 
both limited by morbidity and availability. Stroke, peripheral artery disease (PAD), and other 
cardiovascular pathological conditions also claim millions of victims each year with high 
morbidity and mortality. The total cost of CVD and stroke in the United States alone reaches 
$500 billion annually, making it one of the most poignant clinical problems in modern medicine 
[65].  
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2.2 CARDIOVASCULAR REGENERATIVE MEDICINE 
In the past decade, regenerative medicine has emerged as a futuristic option for treating CVD 
[67-69]. Among which, stem cell therapy is deemed promising due to the multiple advantages of 
stem/progenitor cells, such as differentiation capacity, high proliferation, self-renewal, resistance 
to stress, and trophic effect [70-72]. The recent discoveries of multipotent stem/progenitor cells 
residing in the adult human blood vessel walls further fuel the promise of this new approach in 
cardiovascular applications [1, 25, 26, 47]. Current stem cell-based therapies for CVD primarily 
involve the transplantation of exogenous stem/progenitor cells into the diseased/damaged organs 
[70]. Ideally, donor cell populations need to possess desirable properties for transplantation, for 
example, high availability and easy accessibility with minimal morbidity, high expansibility in 
vitro with no tumorigeneity, high efficiency to restore impaired organ structure and function, 
autologous origin to eliminate immunogenicity, ability to integrate into recipient tissue, minimal 
side effects, and no ethical controversy [15, 22, 73-76]. Consequently, autologous multipotent 
stem cells best match the definition of ideal donor cells and are of particular interest over other 
cell types. In the context of MI, a typical human infarct involves an irreversible loss of 1–1.5 
billion cardiomyocytes (CMs) with a subsequent loss in myocardial cell mass [70]. Therefore, 
stem/progenitor cells that contribute to sustain the number of viable and functional CMs hold 
considerable clinical significance. Furthermore, given the vascular pathological nature of CHD, 
autologous stem cells that are capable of repairing host vascular networks and/or regenerating 
new blood vessels, in addition to other merits, would be ideal candidates [17]. 
Several types of adult stem/progenitor cells from multiple organs have been investigated 
not only in the laboratories and but also in the clinical trials. The bone marrow (BM) functions as 
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a reservoir for stem/progenitor cells, housing endothelial progenitor cells (EPCs) and 
hematopoietic stem cells (HSCs), other than BM mesenchymal stem/stromal cells (BM-MSCs). 
Adipose tissue throughout the body contains adipose-derived stem cells (ADSCs) that are 
phenotypically and functionally resembling BM-MSCs [77]. Skeletal muscle harbor committed 
myogenic precursors, skeletal myoblasts, as well as primitive stem/progenitor cells like satellite 
cells and muscle-derived stem cells (MDSCs) [1]. Most of these stem/progenitor cells have been 
demonstrated to be beneficial for treating CVD in the pre-clinical animal models. For example, 
HSCs were shown to occupy up to 68% of the infarcted region and integrate with the damaged 
host myocardium by forming connexin-43 gap junction in animal models [78]. EPCs have been 
successfully applied in cardiac repair for revascularization of the infarcted myocardium [79]. 
However, these precursor cells instead showed uneven success in early-phase human clinical 
trials [15, 16, 22, 23]. On the other hand, owing to their unique properties of high autologous 
availability, multi-lineage plasticity, efficient self-renewal, immune tolerance and regulation, 
paracrine effector release and trophic support, BM-MSCs and associated ADSCs as well as other 
MSC-like multipotent cells, including subpopulations of BVSCs described above, hold great 
promise for cardiovascular repair [72]. 
2.3 MULTI-LINEAGE MESODERMAL STEM/PROGENITOR CELLS FOR 
CARDIOVASCULAR REPAIR 
Since the first discovery of mesenchymal stem/stromal cells (MSCs) in the stromal compartment 
of BM, MSCs or MSC-like multipotent stem/progenitor cells have been identified in many other 
tissues and organs that are available for therapeutic retrieval, such as fat, placenta, umbilical cord, 
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skin…etc. In brief, MSCs are initially defined as a BM stromal population of 
CD45
−
/CD34
−
/CD133
−
 cells and selected by their adhesiveness to the surface of cell culture 
dishes [80]. MSCs have been shown to differentiate/transdifferentiate into various cell lineages, 
including osteoblasts, chondrocytes, adipocytes, skeletal and cardiac myocytes, smooth muscle 
cells (SMCs), tendon-ligament fibroblasts, marrow stromal cells, and other mesenchymal 
phenotypes [80]. MSCs have apparent immunoprivilege due to their low express level of MHC 
class II molecules, compared with MHC I, and B7 co-stimulatory molecules for MHC class I. 
MSCs also display local immunosuppressive properties, allowing successful transplantation into 
an allogenic setting and long-term engraftment [80]. Besides all these advantages, their easy 
isolation and fast expansion in culture make MSCs a highly desirable candidate for stem cell-
based cardiac therapy (SCCT). 
The use of MSCs for cardiovascular repair utterly matches the underlying objectives 
behind the cardiac regenerative therapy, which subsumes promoting angiogenesis and vascular 
perfusion in the ischemic myocardium, ameliorating cellular apoptosis and enhancing 
myocardial protection, reducing cardiac fibrosis and ventricular remodeling, and finally, 
regenerating the damaged myocardial structures by repopulating lost resident cells (e.g. 
endothelial cells, SMCs, cardiomyocytes, and stromal cells). Several studies have shown that 
injections of MSCs into the infarcted myocardium improve cardiac function. Animal studies 
showed that engrafted MSCs expressed cardiomyocyte markers after 4 weeks, aligned with host 
cardiomyocytes, and formed intercalated discs [81]. Overall, these preclinical studies have 
provided evidence for a beneficial effect of the MSC transplantation on the recovery of cardiac 
functions. 
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2.4 MECHANISMS OF MSC-MEDIATED CARDIOVASCULAR REPAIR 
Following the ischemic insult, cardiomyocytes and the entire cardiac tissue within the affected 
area undergo apoptosis or necrosis if the blood supply is not quickly restored, leading to the 
chronic sequelae of cardiomyopathy and eventually congestive heart failure (CHF) [66]. The 
limited endogenous regenerative capacity of the adult human heart is unable to replenish such a 
substantial loss of myocardial tissue after incidents like AMI. As depicted previously, MSC-
based cell therapies have been shown to significantly improve cardiac function and drastically 
attenuate post-infarction ventricular remodeling. The functional benefit observed after MSC 
transplantation has been attributed to a number of mechanisms: differentiation of MSCs into new 
cellular components; paracrine release of cardiogenic, cardioprotective and tissue remodeling 
agents from MSCs; stimulation of endogenous regeneration via circulatory or resident host cells; 
mechanical buttressing/passive girdling effect from locally increased myocardial thickness [15, 
22, 74, 76]. Any one or a combination of these repair mechanisms directly or indirectly 
contribute to the overall functional recovery. Some of the established repair mechanisms are 
briefly discussed in this section. 
2.4.1 Cardiomyogenesis  
MSCs have been shown to differentiate into cardiac cells, though to a limited extent, under 
inductive conditions in culture and after transplantation in vivo [81]. This cardiomyogenic 
capacity sustains the high hope among investigators that engrafted MSCs regenerate lost cardiac 
tissue by differentiating into cardiomyocytes and integrating with the native myocardium in the 
damaged heart, resulting in a significant contribution to the functional restoration. However, 
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reports from Deb, Hocht-Zeisberg and Nygren demonstrated only a small fraction of bone 
marrow stem cells differentiated into cardiomyocytes in the infarcted hearts [79]. The number of 
newly regenerated cardiomyocytes is too low to fully explain the significant functional 
improvement. Additionally, it remains a daunting challenge to stably reproduce a functional 
cardiac phenotype in MSCs in vitro using physiological and nontoxic reagents. Cell fusion 
between donor cells with recipient cardiomyocytes, thereby preventing apoptosis and improving 
cellular performance, has been suggested to be another contributory factor, but its frequency is 
also debated [82]. In conclusion, regardless of whether cardiomyocyte trans-differentiation of 
MSCs is fusion-independent or not, the observed restoration of cardiac function can only be 
partially attributed to the cardiomyogenesis by MSCs. 
2.4.2 Neovascularization 
Vasculogenesis and neoangiogenesis in the recipient organ can result from trans-differentiation 
of implanted MSCs into endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). 
Participation of MSCs in the formation of new blood vessels ex vivo and in vivo as VSMCs or 
perivascular cells has been displayed. Previous work revealed that bone marrow stem cells that 
integrated into the heart tissue participated more in angiogenesis than myogenesis [79]. Similar 
results were reported in a number of human clinical trials. Nevertheless, the same argument 
regarding the low number of donor cells trans-differentiating into vascular cells to entirely 
explain the increased vascularization stands. Our studies also showed that transplantation of 
MSC ancestors or other mesodermal lineage stem/progenitor cells significantly promote 
angiogenesis and consequently enhance myocardial perfusion in animal models [52, 55, 83]. The 
importance of neoangiogenesis in mesodermal stem cell-mediated cardiac repair was further 
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demonstrated by a linear relationship between angiogenic factors, angiogenesis and cardiac 
functional repair [84].  
2.4.3 Paracrine effects 
MSCs stimulate/mobilize/protect host cardiac cells by releasing an array of cardiogenic and 
cardioprotective molecules. It has been suggested that the favorable effects of MSC 
transplantation are primarily attributed to the paracrine effects of stem cells [85]. MSCs have the 
capacity to secrete angiogenic growth factors such as vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF) as well as cell 
survival growth factors such as insulin-like growth factor-1 (IGF-1) and hepatocyte growth 
factor (HGF) [79]. MSCs also release multi-functional cytokines like interleukin (IL)-1, -6, -11 
and molecules like transforming growth factor (TGF-β) and angiopoietins, which are related to 
vascular cell interactions and support vascular growth, stability, and remodeling [30]. MSCs are 
known to express matrix metalloproteinase (MMP)-1, -2, -9 and tissue inhibitor of 
metalloproteinase (TIMP)-1, -3 in addition to other proteinases/proteinase inhibitors. These 
trophic factors and cytokines secreted by transplanted MSCs may play multiple roles influencing 
neovascularization, myocardial protection, post-injury inflammation, cardiac remodeling, and/or 
host endogenous regeneration, ultimately leading to the improvement of cardiac function [70]. 
Moreover, many of these beneficial molecules were significantly upregulated in MSCs under 
hypoxia, suggesting the possibility that MSCs not only possess advantages for ischemic tissue 
repair but can be enhanced by hypoxic preconditioning [86]. 
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2.5 CLINICAL APPLICATION OF MSC-BASED CARDIOVASCULAR THERAPY 
The therapeutic application of MSCs and MSC-like precursor cells in the clinical setting is 
currently being explored in a number of phase I/II and phase III clinical trials for several 
indications, for instances, CVD, renal pathologies, multiple sclerosis/amyotrophic lateral 
sclerosis, Crohn’s disease, and osteogenesis imperfecta [19, 20]. Due to their remarkable 
immunoregulatory capacities, the use of MSCs to reduce graft-versus-host disease (GvHD) and 
facilitate hematopoietic stem cell (HSC) engraftment has particularly been investigated in several 
studies. An early study (69 patients) reported that at 3 months follow-up, intracoronary injection 
of BM-MSCs significantly improved overall left ventricular function in MSC-treated patient who 
underwent primary percutaneous coronary interventions within 12 hours after the onset of AMI 
[87]. Perfusion defects, detected by positron emission tomography (PET), were significantly 
ameliorated after MSC treatment while electrocardiographic monitoring revealed lack of any 
occurrences of arrhythmia in the MSC-administered subjects [87]. In a recent double-blind study 
(53 patients), intravenous administration of allogeneic hMSCs (Prochymal, Osiris Therapeutics, 
Inc.) in reperfused MI patients, when compared to placebo, significantly reduced ventricular 
tachycardia episodes, increased forced expiratory volume in 1 second (FEV1), and improved 
global condition of patients at 6 months post-treatment [88]. hMSC-treated subjects had 
significantly better left ventricular ejection fraction (LVEF), measured by cardiac magnetic 
resonance imaging (MRI), in through the 12-month follow-up and exhibited evidence of reverse 
remodeling while the adverse event rates and laboratory indexes (renal, hepatic, and hematologic) 
remained no different between hMSC-treated and placebo groups [88]. An observer-blinded 
study (85 patients) utilizing intravenous transplantation of autologous ex vivo cultured BM-
MSCs in patients with ischemic stroke reported improved functional outcomes, measured by 
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modified Rankin Scale (mRS), in a 5-year follow-up without significant side effects or higher 
co-morbidities like seizure [89]. A correlation between the serum level of stromal cell-derived 
factor-1α (SDF-1α) at the time of MSC-treatment and clinical improvement was observed within 
the MSC group, implicating the importance of chemokines in MSC recruitment and a potential 
biomarker for candidate patient selection [70, 89]. Novel MSC-based cell therapies for 
indications like insulin-dependent diabetes mellitus (IDDM), acute lung injury (ALI), and other 
diseases which broadly relate to CVD are also under intense investigation [90, 91]. Thus far most 
phase I/II trials reported that MSC administration is safe with absence of major adverse effects or 
associated toxicity, suggesting the feasibility to further pursue clinical translation of MSC-based 
cardiovascular therapies  [19]. 
2.6 ENHANCEMENT OF MSC-BASED CARDIOVASCULAR CELL THERAPY 
Despite the promising results of interventions with stem cells in animal disease models, until 
now, clinical studies have in general not been able to live up to the same expectations. Typical 
problems limiting the efficacy of MSC cell therapy in the cardiovascular milieu include: 1) poor 
viability of the transplanted grafts due to the hostile microenvironment; 2) low rate of 
engraftment and/or homing of donor cells; 3) lack of evidence on MSC behavior and 
differentiation in the recipient heart; 4) limited knowledge on the timing and modality of 
administration. Indeed, in most studies, only 1-5% of delivered cells successfully engrafted 
within the ischemic area for the long term. Hence there is an urgent need to overcome these 
limitations and enhance the therapeutic efficacy of MSCs. Several new strategies of ex vivo 
manipulation of MSCs have been applied successfully in the laboratories and in animal models 
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such as preconditioning of MSCs before transplantation to maximize cell survival, priming of 
MSCs to increase cell functionality and differentiation, and better delivery modality to minimize 
tissue damage [70]. A few of the most striking progresses will be reviewed in this section. 
2.6.1 Improving MSC survival and engraftment  
There are many causes of donor cell death in the ischemic myocardium. It may start with anoikis, 
the programmed cell death induced by loss of extracellular matrix (ECM) attachments, leading to 
cellular apoptosis [80]. Once MSCs are transplanted into the infarcted area, cells immediately 
encounter the harsh conditions (e.g. deprivation of nutrients and oxygen), deficiency of survival 
factors, and inflammation) coupled with excessive oxidative stress and apoptotic signals, all of 
which shorten the longevity of donor MSCs. Myocardial injury generates an inflammatory 
response mediated by neutrophils and macrophages, which produce inflammatory cytokines and 
reactive oxygen species (ROS) that may initiate apoptotic signaling pathways or lead to death of 
grafted cells [80]. The hostile recipient microenvironment further impedes physiological function 
and differentiation capacity of donor cells, resulting in low rate of homing, engraftment and 
regeneration.  
In order to minimize the massive cell death after transplantation, measures were taken to 
promote engraftment and survival of donor cells via ex vivo preconditioning before 
transplantation [92]. These approaches include exposure of MSCs to physical treatments (i.e. 
hypoxia and heat shock) to stimulate cellular production of growth factors and internal survival 
signals, and treatment of pharmacological agents like anti-oxidants to enhance the capacity of 
cells against oxidative stress. Results from several studies demonstrated the effectiveness of ex 
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vivo preconditioning in increasing the engrafted cell number [80]. Drowley et al. reported that 
treating MDSCs with N-acetylcysteine (NAC) to increase cellular anti-oxidant level significantly 
enhance cell survival under inflammatory and oxidative stresses in culture and further improve 
post-infarction cardiac function after transplantation [71]. Erythropoietin, a hematopoietic 
cytokine, was shown to mobilize and stimulate the recruitment and survival of bone marrow–
derived progenitor cells to the heart. Priming of MSCs with growth factors and genetic 
modification by over-expression of anti-apoptotic or pro-survival genes aim to achieve similar. 
MSCs that were genetically modified to overexpress Akt, SDF-1, or IGF-1 before transplantation 
are shown to survive and function better. These preconditioned or modified MSCs have yielded 
promising results and been proclaimed to stimulate the survival and cardioprotective pathways in 
the infarcted myocardium. However, to develop the ultimate strategy with maximal enhancement 
of engraftment, survival and function of MSCs in the ischemic heart may require a combination 
of approaches and remains a challenge for years to come. 
2.6.2 Augmenting MSC cellular function  
BM-derived cells isolated from patients with CHD risk factors exhibited a reduced capacity to 
promote neovascularization after ischemia [93], and several studies aimed to rescue the defective 
cellular properties. HMG-CoA reductase inhibitors, statins, were shown to increase the number 
of EPCs and enhance their migratory and survival capacity [92, 94]. Preconditioning of EPCs 
with statins increased their neovascularization-promoting effect. Mechanisms by which statins 
affect the functions of cells are not yet entirely clear but may involve the activation of PI3 kinase 
and Akt and subsequent activation of the endothelial nitric oxide (NO) synthase. Aging and 
cellular senescence also contribute to stem/progenitor cell dysfunction, causing decreased 
 28 
restorative and regenerative capacities [95]. New evidence suggests that age-dependent 
functional impairment of stem/progenitor cells can be corrected by growth factors like IGF-1. 
Moreover, statins have been shown to partially antagonize progenitor cell senescence via 
activation of the PI3 kinase/Akt pathway. Therefore modulation of IGF-1 and/or Akt signaling 
system may be useful in regenerative therapies using MSCs isolated from elder or high risk 
patients. 
2.6.3 Promoting cardiac regenerative capacity 
Albeit recent studies provide convincing evidence that new cardiomyocytes can be generated in 
the human heart throughout the adult life [96], under severe pathological conditions in which 
larger numbers of cardiomyocytes are lost and/or malfunctioning, the endogenous regenerative 
system is insufficient to compensate the functional deficiency [94]. Due to their highly active 
paracrine capacity in the injured heart, transplantation of MSCs not only exert cardioprotective 
and neoangiogenic functions but may stimulate or reactivate the endogenous regeneration, e.g. 
by paracrine stimulation of resident cardiac stem cells or cardiomyocyte progenitor proliferation. 
Treatment of target tissue with FGF-2, IGF-1, or a combination of FGF-2, IGF-1 and bone 
morphogenetic protein-2 (BMP-2) were shown to improve cardiac function in animal models 
[92], all of which were part of the secretory portfolio of MSCs. These growth factors exhibit a 
wide range of influences (e.g. anti-apoptotic activity, pro-angiogenic effects…etc.) and may 
contribute to cardiac differentiation of stem cells. On the other hand, mixed results were reported 
regarding the engraftment and cardiac differentiation of various exogenous stem/progenitor cells 
in the injured heart [92, 94]. Though the number of implanted donor cells forming 
cardiomyocytes may not reach a functionally meaningful level, researchers continue pursuing 
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measures to drive adult stem/progenitor cells to acquire a cardiac fate. Wnt-11, required for 
cardiopoiesis in Xenopus, and other noncanonical members of the Wnt family such as Wnt-5a 
were reported to induce or enhance cardiac gene expression in adult progenitor cells and promote 
of cardiac differentiation. Over-expression of Wnt-11 increased the number of MDSCs or MSCs 
to differentiate toward cardiomyocytes in culture and in vivo [92, 97]. 
2.6.4 Changing cell delivery modality  
Conventional delivery methods involve intramyocardial or intracoronary injections of MSCs into 
the ischemic myocardium, which often lead to substantial loss of cells and inadequate adhesion. 
Cell sheet technology, a new cell delivery modality based on the formation of sheet-like 
structures by culturing cells on a temperature-responsive poly(N-isopropylacrylamide) surface, 
has the advantage of maintaining cell-cell contact that promote cell survival and functionality 
[98]. Memon et al. found that myoblast cell sheets implanted with intact culture matrix onto the 
surface of infarcted rat hearts improved cardiac outcomes when compared with direct injection 
of myoblasts. This new approach not merely enhanced the survival of implanted cells but also 
diminished the arrhythmic events associated with the transplantation. Our recent study also 
suggested that MDSC cell sheets repair the infarcted hearts and reduce the arrhythmic events 
more efficiently than intramyocardial cell injections (Sekiya et al., in revision). Additionally, 
successful engraftment of human embryonic stem cell (hESC)-derived cardiomyocytes was 
enhanced by co-delivery of stem cells with collagen matrices, including Gel Foam and Matrigel, 
a basement membrane preparation, indicating the importance of cell-ECM interaction [80].  
 30 
2.6.5 Enhancing homing/recruiting signaling 
Recruitment of stem/progenitor cells to the ischemic site requires activation and attraction by 
chemokines. Stromal derived factor-1 (SDF-1) and its receptor CXCR4 are well established to be 
essential for hematopoietic progenitor cell recruitment and angiogenesis [99]. The expression of 
CXCR4 receptor on EPCs and BMCs is stimulated by the up-regulation of SDF-1 during acute 
ischemia, thereby functioning as chemotactic and pro-migratory signals. Injection of cytokines to 
improve endogenous progenitor cell recruitment was demonstrated by local injections of SDF-1 
in ischemic hind limbs which increased the recruitment of intravenously infused EPCs [92]. 
Activation/over-expression of the CXCR4 receptor may thus provide an option to enhance MSC 
recruitment. By increasing the extracellular calcium concentration, the transcription and surface 
expression of CXCR4 is stimulated, leading to enhanced recruitment of progenitor cells and 
augmented neovascularization. Reduction of SDF-1 cleavage by inhibition of CD26 
dipeptidylpeptidase or mutation of the cleavage site showed increases in BM-derived progenitor 
cell recruitment and functional recovery after myocardial ischemia. MSCs that are genetically 
modified to over-express SDF-1 may further enhance both donor and host stem cell homing [92]. 
In addition, immune cells in the ischemic tissue release chemokines such as interleukins and 
monocyte chemoattractant protein-1 (MCP-1), which are involved in the homing of adult BM-
MSCs to the ischemic hearts [100]. 
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2.7 PERIVASCULAR ORIGIN OF MSCS 
As development reaches the adult maturity, stem cells rarefy, and tissue growth and renewal 
become marginal, making it difficult to trace the anatomical locations of stem cells in the human 
body. MSCs [101], along with several other adult multi-lineage stem cells including multipotent 
adult progenitor cells (MAPCs) [102], muscle-derived stem cells (MDSCs) (reviewed in [1]) and 
adipose-derived stem cells (ADSCs) [103], were retrospectively identified in tissue cultures, 
leaving no clue to their native location and physiological role. Without apparent conformational 
traits of the stem cell niche, for example, crypts in the intestine, sarcolemma in skeletal muscle, 
and the bulge of hair follicles, it is nearly impossible to identify stem cells in situ within their 
natural microenvironment. Consequently, the true identity of these cells has remained elusive for 
many years, which in turn hinders further understanding of adult stem cell biology. Nonetheless, 
the omnipresence of MSCs and identification of multipotent stem cells with similar 
characteristics and developmental potentials in virtually all postnatal organs raised the possibility 
that a common source of supply may exist in the body.  
As mesodermal stem/progenitor cells have been successfully extracted from most of the 
adult mouse and human organs such as bone marrow, fat, skin, skeletal muscle, dental pulp, 
placenta, umbilical cord and others, we hypothesized that a structure anatomically common to 
these organs represents the mysterious regenerative unit. Blood vessels present in all of these 
organs naturally stood out as the top candidate tissue. Indeed, blood vessels are known to 
contribute non-vascular cells such as hematopoietic cells [104] and myogenic cells [45] and has 
been applied to facilitate tissue repair in the clinical setting [105]. We and others recently 
reported evidences supporting the contention that perivascular cells constitute, at least in part, the 
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reservoir of multi-lineage mesodermal stem/progenitor cells distributing throughout the human 
body [26, 46].  
Perivascular cells around capillaries and microvessels (arterioles and venules), namely 
pericytes, closely ensheath endothelial cells and are commonly regarded as the structural 
components of blood vessels that regulate vascular contractility and support the stability of blood 
vessels [30]. Through the selection of a combination of positive and negative cell lineage 
markers, pericytes (CD146
+
CD34
-
CD45
-
CD56
-
) can be prospectively purified to homology by 
fluorescence-activated cell sorting (FACS) from fresh biopsies of multiple human organ [26]. 
FACS-purified pericytes express perivascular surface antigens: CD146, NG2, PDGFR-β, 
alkaline phosphatase (ALP) [26, 46] with absence of hematopoietic cell marker CD45 and 
endothelial cell markers: CD31, CD34, CD144, vWF, and UEA-1 ligand. Most importantly, 
pericytes strongly express the classical MSC markers: CD44 CD73, CD90 and CD105, natively 
and in culture and possess osteo-, chondro-, adipo-, and myogenic differentiation competence 
[26]. These perivascular cells can be clonally expanded and long-term cultured with no alteration 
to their phenotypes and developmental potentials. The high repair/regenerative capacities of 
pericytes were not only demonstrated in injured and dystrophic skeletal muscles
 
but also in 
infarcted hearts in mouse disease models [17, 26, 55]. Consequently, we postulated the 
developmental correlation between MSCs and pericytes, a ubiquitously distributed reserve of 
multi-lineage stem/progenitor cells, and concluded by the likely perivascular origin of MSCs. 
Other tissue-specific stem/progenitor cells, for instance, osteogenic, odontoblastic, and 
adipogenic progenitors have been suggested to originate from perivascular niches in vivo, in 
agreement with the robust osteogenic and adipogenic properties of purified pericytes and the 
common origin from blood vessels [9, 61, 106]. Although it remains to be clarified whether these 
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tissue-specific stem/progenitor cells derive from or belong to one or more distinct vascular cell 
population(s), a tight connection between adult stem/progenitor cells and their 
vascular/perivascular niches has been established. Future investigations are required to elucidate 
the significance of this anatomical localization to the pathophysiology of tissue-specific 
stem/progenitor cells and their regenerative capacities. 
2.8 CONCLUSION 
In this chapter, I discussed therapeutic applications, repair mechanisms, and future strategies of 
MSCs and MSC-like precursor cells in CVD, with an emphasis on ischemic heart disease. 
Overall, multipotent mesodermal precursors represent a very promising and clinically available 
source of adult stem cells in cardiovascular applications, with their safety being demonstrated by 
recent clinical trials. Nevertheless, additional efforts will be required to further improve their 
salutary efficacy and delivery modality. With the fast advances in the mechanistic understanding 
of MSC-mediated tissue restoration, new approaches can be developed to maximize their 
sanative capacity in the cardiovascular milieu, including preconditioning and genetic 
modification of MSCs. The recent discovery of the likely perivascular origin of MSCs provides 
us with in-depth understanding of their native microenvironment and distributions as well as 
their physiological and pathological roles in the human body. The identification of multiple 
mesodermal stem/progenitor cell populations within the walls of blood vessels of all sizes further 
suggest the complexity of MSCs and stem cell biology as a whole. A continual joint effort by 
scientists and clinicians will be needed to pursue the futuristic personalized regenerative 
medicine using adult stem cells: a stem cell treatment plan tailored for individual patient. 
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3.0  HUMAN PERICYTES FOR ISCHEMIC HEART REPAIR 
3.1 INTRODUCTION 
Coronary heart disease (CHD) is the leading cause of death in the United States, affecting 16.3 
million people and accounting for 1 of every 3 deaths in 2007 [107]. Prolonged pathological 
interference with the coronary blood supply, such as atherosclerosis and thromboemboli, results 
in ischemic cardiomyopathy and/or myocardial infarction (MI) [108]. MI often leads to heart 
failure (HF) due to the limited capacity of the human heart to repair/regenerate its damaged 
myocardium [108, 109]. Stem/progenitor cell-based cardiac therapy (SCCT), as an alternative to 
heart transplantation, is deemed promising for restoration of cardiac function and prevention of 
progressive HF because of manifold advantages [15, 109]. Specifically, human stem/progenitor 
cells, including skeletal myoblasts, bone marrow cells, endothelial progenitor cells, and 
endogenous cardiac progenitor cells, have been intensively investigated with uneven success in 
pre-clinical and clinical trials [15, 109-111]. Given the vascular origin of CHD pathology, 
stem/progenitor cells that are capable of reconstituting host vascular networks, in addition to 
other merits, will be ideal cell sources for SCCT. 
Microvascular pericytes (aka mural cells) have recently been discovered to include 
stem/progenitor cells endowed with mesodermal differentiation potentials and suggested to be 
one of the several developmental origins of heterogeneous mesenchymal stem (aka stromal) cells 
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(MSCs) [26, 46, 47, 61-63, 112]. Multipotent pericytes isolated from human skeletal muscle, 
adipose, placenta, and pancreas repair and regenerate damaged/defective organs [26, 46, 112-
114]. Owing to their wide distribution throughout the microvasculature, pericytes are regarded as 
a promising and attractive source of stem cells for regenerative medicine [17, 115]. 
Microvascular pericytes tightly encircle capillaries and microvessels (arterioles and venules) and 
regulate microvascular physiology [30]. Above all, due to their native vascular localization, 
pericytes may restore injured vascular networks more efficiently. We hypothesized that SCCT 
with pericytes is a suitable approach for the treatment of ischemic heart disease (IHD) [55].  
Besides cardiomyogenesis, cardioprotective mechanisms, e.g. neovascularization, anti-
fibrosis and anti-inflammation actions, play critical roles in SCCT-mediated cardiac repair 
following ischemic insults [72, 85]. To relieve the underlying cause of IHD, SCCT-based 
approaches toward myocardial revascularization have been extensively pursued [24, 116]. Pro-
angiogenic signaling molecules released by stem/progenitor cells stimulate neovascularization in 
ischemic tissues [24]. Pericytes do secrete trophic factors associated with tissue repair and 
vascular growth/maturation/remodeling [17]. Nevertheless, cell-cell interaction between mural 
cells and endothelial cells was lately suggested to play essential roles in blood vessel remodeling 
and maturation [117-119]. It remains to be tested whether multiple angiogenic/vasculogenic 
mechanisms are involved in pericyte-mediated revascularization of the ischemic myocardium.    
To prevent the progressive, pathological decline toward heart failure, favorable tissue 
remodeling after MI is deemed important. Mesodermal stem/progenitor cells reduce myocardial 
fibrosis and subsequently increase myocardial compliance and strength in the ischemic heart 
[120, 121]. This anti-fibrotic feature was attributed to increased collagen degradation by matrix 
metalloproteinases (MMPs), decreased collagen production, and inhibition of fibroblast 
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activation, possibly through a paracrine mechanism [122, 123]. Additionally, the 
immunosuppressive/anti-inflammatory capacity of MSCs has recently attracted clinical attention 
in organ transplantation and immune regulation [124, 125]. This immunoregulatory activity was 
primarily associated with secretion of interleukin (IL)-6, prostaglandin E2 (PGE2), leukemia 
inhibitory factor (LIF), and heme oxygenase-1 (HMOX-1) [124, 125]. Whether pericytes possess 
such an immunoregulatory capacity within the ischemic microenvironment remains to be 
addressed. 
In the present study, we investigated the therapeutic potential of purified human skeletal 
muscle pericytes in IHD, using an acute MI (AMI) model in immunodeficient mice. 
Transplantation of pericytes not only reversed cardiac dilatation but also improved cardiac 
contractility. Four major healing mechanisms were investigated: promotion of angiogenesis, 
reduction of fibrosis, inhibition of chronic inflammation, and regeneration of the myocardium. 
We further describe putative mediators employed by pericytes in each mechanism. GFP-labeling 
was used to track the homing and lineage fate of engrafted pericytes. Our results demonstrate 
that the overall benefit of pericyte treatment is collectively attributed to multiple cardioprotective 
mechanisms that involve paracrine and direct cell-cell interactions. 
3.2 METHODS 
3.2.1 Human tissue biopsies 
In total, 3 independent human skeletal muscle specimens (1 adult and 2 fetal) were used for cell 
isolation. The procurement of adult muscle biopsies from the National Disease Research 
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Interchange was approved by the Institutional Review Board (IRB) at the University of 
Pittsburgh Medical Center. Muscle biopsies (male subjects, 57 and 70 years old) were preserved 
in DMEM containing 1% antibiotics and transported to the laboratory on ice. Human fetal tissues 
(19-23 weeks of gestation) were obtained following voluntary pregnancy interruptions performed 
at Magee Womens Hospital, in compliance with IRB protocol 0506176. Informed consents for 
the use of fetal tissues were obtained from all patients.  
3.2.2 Fluorescence-activated cell sorting (FACS) and flow cytometry analysis 
Microvascular pericytes present in the adult and fetal skeletal muscles were purified by FACS as 
previously described
7
. Briefly, fresh muscle biopsies were minced and digested with 
collagenases I, II and IV (1 mg/mL, Sigma) at 37ºC for 1 hour. Cells were washed and 
sequentially filtered through 100- and 70-μm cell strainers (BD Falcon) to obtain single cell 
suspension. Cells (5-10x10
6
) were incubated with one or all of the following directly conjugated 
mouse anti-human antibodies (all with 1:100 dilutions): anti-CD34-PE (DAKO), anti-CD45-
APC-Cy7 (Santa Cruz), anti-CD56-PE-Cy7 and anti-CD146-FITC (both Serotec) at 4ºC for 20 
min in the dark. As negative controls, isotype-matched mouse IgGs conjugated to PE 
(Chemicon), APC-Cy7 (Becton-Dickinson), PECy7 and FITC (Chemicon), were used. After 
washing, all labelled cells were incubated with 7-amino-actinomycin D (7-AAD) (BD, 1:100) for 
dead cell exclusion and subsequently sorted on a FACSAria flow cytometer (BD).  
For quality control, flow cytometry was employed to examine the expression profile of 
cell lineage markers. Cultured pericytes at different passages were trypsinized and labelled with 
the following directly conjugated antibodies (all with 1:100 dilutions): anti-CD34-PE (BD), anti-
CD44-PE (BD), anti-CD45-PE-Cy7 (Beckman Coulter), anti-CD56-PE (Chemicon), anti-CD73-
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PE (BD), anti-CD90-APC (Chemicon), anti-CD105-PE (ImmunoTools) and anti-CD146-FITC 
(Serotec) for 20 min at 4ºC in the dark and subsequently analyzed on a FACSAria flow 
cytometer. For analysis of alkaline phosphatase (ALP) expression, cells were incubated with 
anti-human ALP (Biogenesis, 1:30) and then with donkey anti-sheep Ig-FITC (Serotec), each for 
20 min at 4°C. 
3.2.3 Cell culture and cell labelling 
Sorted human microvascular pericytes were expanded and maintained in Dulbecco's modified 
eagle medium (DMEM) high glucose (Gibco) supplemented with 20% FBS and 1% 
Penicillin/Streptomycin (P/S) as previously described
7
. Cell morphology and the cell surface 
marker expression were monitored to ensure the quality of cells, using formerly published 
methods and criteria
7
. Single donor-derived human umbilical cord vein endothelial cells 
(HUVECs) were purchased from Lonza and cultured in endothelial cell growth medium 2 
(EGM-2, Lonza), following the manufacturer’s instructions.  
For gene transfer of green fluorescence protein (GFP), cultured pericytes at passages 7-10 
were detached with 0.25% trypsin-EDTA (Gibco) and seeded at a density of 10,000 cells per cm
2
.
 
After 24-48 hours, when the culture reached 60-70% confluence, the medium was replaced with 
transduction medium (α-MEM, 10% FBS, 1% P/S, and 8 g/mL polybrene), and a lentivirus-
based CMV-driven eGFP expression vector
 
was added at a MOI of 10. Following incubation for 
16-18 hours at 37ºC, the transduction medium was removed and replenished by complete culture 
medium. Three days later, nearly 100% of cells expressed GFP. GFP-labeled cells were further 
expanded for 1-2 passages without significant adverse effect. For short-term in vitro experiments, 
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cells were labelled with cell membrane dye, PKH26 (Red) and PKH67 (Green) (Sigma-Aldrich), 
following the manufacturer’s instructions. Dye-labelled cells were used for experiments 
immediately after labelling without further expansion. 
3.2.4 Intramyocardial cell transplantation in acute myocardial infarction (AMI) model 
The Institutional Animal Care and Use Committee at Children’s Hospital of Pittsburgh of UPMC 
and University of Pittsburgh approved the animal usage and surgical procedures performed in 
this study (Protocol 37-04, 55-07, and 0901681A-5). A Total of 64 male NOD/SCID mice 
(Jackson Laboratory, Bar harbor, ME, USA) were used for this study.  
After the induction of anesthesia, mice were intubated and inhalationally anesthetized 
with 2% isoflurane gas throughout the surgery. Myocardial infarction (MI) was induced by 
ligation of the left anterior descending coronary artery (LAD). Five minutes after the induction 
of infarction, 3x10
5 
cells in 30µl of PBS were injected into three sites (center and two borders of 
the infarct) of the myocardium. Control mice received either injection of 30µl PBS or no 
injection (MI sham) following AMI. The investigator creating the infarction injury and 
performing the injection was blinded to the content of the injectant, excluding the MI sham 
group. 
3.2.5 Evaluation of cardiac function by echocardiography 
Echocardiographic studies were performed by a blinded investigator repeatedly at 2 and 8 weeks 
after surgery to assess the cardiac function of anesthetized mice, as previously described
27
. End-
systolic dimension (ESD) and end-diastolic dimension (EDD) were determined from the short 
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axis images of the LV and measured from at least six consecutive beats using the M-mode 
tracing. End-systolic area (ESA) and end-diastolic area (EDA) were measured from short-axis 
images of the LV. Fractional shortening (FS), an index of LV contractility, was calculated as FS 
(%) = [(EDD-ESD)/EDD] x 100. FAC (Fractional Area Change), another index of LV 
contractility, was calculated as FAC (%) = [(EDA-ESA)/EDA] x 100. Mice died or sacrificed for 
histological analysis prior to 8 weeks post-injection were not included in the echocardiographic 
study. 
3.2.6 Histological and immunohistochemical analyses  
Animals were sacrificed at 1, 2, and 8 weeks post-surgery. Hearts were arrested in diastole by 
intraventricular injection of 1M potassium chloride (KCl) and processed as formerly described
27
. 
Harvested hearts were flash frozen in 2-methylbutane (Sigma) pre-cooled in liquid nitrogen and 
serially cryosectioned at 6-8 µm thickness from apex to the ligation level (approximately 0.5 mm 
in length). Each series contains 21-24 heart sections, which are roughly 200 um apart originally 
and collected on one glass slide. Sections were fixed in a pre-cooled (-20°C) mixture of methanol 
and acetone (1:1) for 5 min or in 4% paraformaldehyde for 8 min prior to staining. Hematoxylin 
and eosin (H&E) staining was performed following the standard protocol. Non-specific antibody 
binding was blocked with 5% donkey or goat serum for 1 hour at room temperature (RT) and, if 
necessary, with the Mouse-on-Mouse (M.O.M.) antibody staining kit (Vector). 
For homing and cell fate tracing, anti-GFP immunofluorescent staining was employed to 
detect GFP signals. Briefly, after fixation in paraformaldehyde and blocking, sections were 
permeabilized with 0.1% Triton in PBS and incubated at 37°C for 1 hour with rabbit anti-GFP 
antibody (Abcam, 1:1000), followed by incubation with donkey anti-rabbit-Cy3 IgG (Jackson 
 41 
Immunoresearch, 1:250) or donkey anti-rabbit-Alexa
TM
488 IgG (1:250, Molecular Probes) for 1 
hour at RT. To examine homing of donor cells, sections were then incubated overnight at 4°C 
with rat anti-mouse CD31 antibody (1:100, BD), followed by goat anti-rat-Alexa
TM
488 IgG 
(Molecular Probes, 1:400) or donkey anti-rat-Alexa
TM
555 IgG (Molecular Probes, 1:400). To 
examine expression of cardiomyocyte, smooth muscle cell, and endothelial cell markers as well 
as human VEGF165, sections were first stained for GFP and then incubated overnight at 4°C with 
goat anti-cardiac troponin I (Abcam, 1:200), mouse anti-human SM-MHC (DAKO, 1:50), sheep 
anti-human CD31 (R&D systems, 1:50), or goat anti-human VEGF165 (R&D systems, 1:50) 
primary antibody, followed respectively by donkey anti-goat Alexa
TM
555 IgG, donkey anti-
mouse Alexa
TM
555 IgG, and rabbit anti-sheep Alexa
TM
555 IgG (Molecular Probes, all 1:400). 
For evaluation of chronic inflammation, sections were incubated overnight at 4°C with rat anti-
mouse CD68 primary antibody, followed by goat anti-rat-Alexa
TM
488 IgG. Cell nuclei were 
stained by DAPI. 
3.2.7 Quantification of donor cell engraftment and perivascular homing 
To estimate the number of donor cells engrafted in the infarcted heart, quantification was 
performed on anti-GFP immunostained serial cryosections, using a digital image analyzer (Image 
J). The number of GFP-positive cells (nuclei identified by DAPI) present in each heart 
cryosection was computed. The total number of GFP-positive cells within each heart was 
extrapolated as the sum of the number of GFP-positive cells in all serial sections (21-24 sections) 
times the number of section series, corrected by a collection loss coefficient of 20%. The 
engraftment ratio was defined as the extrapolated total number of engrafted GFP-positive cells to 
the initial injection of 3x10
5 
cells. To estimate the number of donor cells that exhibited 
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perivascular homing, quantification was performed on anti-GFP and anti-mouse endothelial cell 
marker, CD31, dual-immunostained serial cryosections, using Image J. Perivascular homing was 
defined as GFP-positive cells juxtapose CD31-positive mouse endothelial cells. The number of 
perivascular homing GFP-positive cells in each heart cryosection was computed. The total 
number of perivascular homing GFP-positive cells within each heart was extrapolated using the 
same formula described above. The perivascular homing ratio was defined as the extrapolated 
number of perivascular homing GFP-positive cells to the extrapolated total number of engrafted 
cells.    
3.2.8 Quantification of host angiogenesis and chronic inflammation 
To quantify host angiogenesis in the heart, immunohistochemistry using anti-mouse endothelial 
cell marker, CD31, was performed on cryosections. The capillary density, represented by the 
number of CD31-positive capillary structures per mm
2
, was subsequently computed from 6 
representative images of the peri-infarct area or infarct region of each heart at the mid-infarct 
level, using Image J as described previously
27
. To evaluate chronic inflammation within the 
infarct region, we performed immunofluorescent staining of anti-mouse CD68 on cryosections 
and subsequently computed the infiltration index, represented by the number of CD68-positive 
host cells per mm
2
, from 8-10 images covering the entire infarct region of each heart at the mid-
infarct level, using Image J. 
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3.2.9 Measurement of Cardiac Fibrosis and Infarct Wall Thickness  
Masson’s trichrome staining kit (San Marcos) was used to stain collagen deposition on 
cryosections, following the manufacturer’s instructions. The area of the collagen deposition, 
representing cardiac fibrosis, and the area of the entire cardiac tissue (excluding the void space in 
the chamber cavity) were measured using Image J. Fibrotic area fraction was estimated as the 
ratio of fibrotic tissue to the entire cross-sectional area of cardiac tissue and averaged from 6 
representative sections per heart. Left ventricular wall thickness at the center of the infarct was 
estimated as the mean of 3 adjacent measurements (0.25mm apart) and was averaged from 6 
representative sections per heart.  
3.2.10 Hypoxia Assay 
To assess the influence of the hypoxic microenvironment in human pericytes, we cultured cells 
under 2.5% O2 hypoxic conditions in vitro as formerly described
27
. Concisely, pericytes were 
seeded in 6-well culture plates at 10,000 cells/cm
2
 and allowed the cells to reach 80-90% 
confluence under normoxia. Upon the transition to low O2 conditions, the complete culture 
medium was removed and cells were washed twice with PBS before defined, serum-free DMEM 
medium was added. Twenty-four hours later, cells were trypsinized and counted. The culture 
supernatant and cell pellets were collected for analysis. Cells cultured under normoxia with the 
serum-free medium served as controls. 
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3.2.11 Semi-quantitative RT-PCR and Real-time Quantitative PCR (real-time qPCR) 
3.2.11.1 Semi-quantitative RT-PCR  
For semi-quantitative RT-PCR (sqRT-PCR), cells were lysed with RLT-plus lysis buffer 
supplemented with beta-mecaptoethanol. Total RNA (N=3) were extracted with the Qiagen 
RNeasy plus-mini-kits. RNA concentration was measured using TECAN plate reader system 
with the NanoQuant measurement program. From each sample, 500ng of total RNA were reverse 
transcribed with SuperScript
TM
 III cDNA synthesis kits (Invitrogen) in 20 µl reactions. PCR was 
performed in 25 µl reaction with Promega Gotaq system and reacted in Vapo.Protect PCR 
machine (Eppendorf) using the following program: 3 minutes for the initial denature, 32 cycles 
at (94°C for 30 seconds, 55°C for 30 seconds, 72°C for 45 seconds) and final extension for 6 
minutes. PCR products were verified by 1% agarose gel electrophoresis. Images were captured 
using the GelDoc system with Quantify One 4.6.2 software. The intensities of the target gene 
bands were quantified using the same software, and normalized to those of the house keeping 
gene β-actin. 
3.2.11.2 Real-time qPCR 
For real-time qPCR, total RNA (N=6) was extracted from 1x10
5
 cells using the Nucleospin RNA 
kit (Clontech). cDNA was synthesized with SuperScript
TM
 II reverse transcriptase (Invitrogen), 
according to the manufacturer’s instructions. cDNA and primers were added to SYBR Green 
PCR master mix (Applied Biosystems) according to the manufacturer’s instructions. The 
quantitative analyses were carried out in triplicate on an ABI Prism 7900HT sequence detection 
system in the core facility of the Genomics and Proteomics Core Laboratories of the University 
of Pittsburgh. All data were normalized to human cyclophilin, which was used as an internal 
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control. Gene expression levels were analyzed using SDS 2.2 Software (ABI) and calculated 
based on the comparative ∆CT method (separate tubes). Data are presented as normalized 
expression level (in arbitrary units). Sequences of target gene primers/probes (IDT-Integrated 
DNA Technologies) used in real-time qPCR and sqRT-PCR are listed below in Table 2 and 
Table 3 respectively. 
Table 2: Primer sequences for real-time qPCR 
 
 
 
 
 
Gene Forward Reverse 
bFGF NM002006 ccgttacctggctatgaagg tttccttgaccggtaagtattg 
HGF NM000601 atatgtgctggggctgaaaa cacgaccaggaacaatgaca 
VEGF-A NM001025368 gcgaggcagcttgagttaaa ctttcctggtgagagatctgg 
EGF NM001963 ggtactctcgcaggaaatgg tccaccaccaattgctcata 
PDGF-β CU013138 tcccgaggagctttatgaga gggtcatgttcaggtccaac 
TGF-β1 NM000660 cgactactacgccaaggaggt cggagctctgatgtgttgaa 
Flt-1 NM002019 cttcacctggactgacagca acagctggaatggcagaaac 
Flk-1 NM002253 tgctcaagacaggaagacca cttcgatgctttccccaata 
PDGFRβ NM002609 catcagcagcaaggacaccat gaccttggtgtctagagagtcc 
IGF-1 X57025 gctggtggatgctcttcagt aagcagcactcatccacgat 
MMP-2 NM004530 gctcccggaaaagattgatgc acctagatgagtcggtcgtg 
MMP-9 BC006093 ttccctggagacctgagaac ctacgcacctctcagcttta 
Cyclophilin catctgcactgccaagactga gcaaagtgaaagaaggcatgaa 
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Table 3: Primer sequences for semi-quantitative RT-PCR 
3.2.12 Vascular network formation in vitro 
To demonstrate the vascular cell characteristics and the supportive function of cultured pericytes, 
we performed cell culture and co-culture experiments using 2D and 3D Matrigel systems and 
observed capillary-like network formation. In brief, 350µl of Matrigel (BD) was placed in each 
well of a 24-well plate and incubated at 37°C for 30 min. Fifty thousand
 
pericytes were 
resuspended in 700µl of EGM2 and seeded onto the Matrigel-coated well. Experiments using 
5x10
4
 HUVECs were performed as controls. A 2D co-culture system using cells pre-labeled with 
cell membrane dye (PKH fluorescent dye, Sigma-Aldrich) was developed to observe pericyte-
Gene Forward Reverse 
IL-6 NM000600.3 ccacaagcgccttcggtcca gtggctgtctgtgtggggcg 
LIF M63420.1 acgccaacggcacggagaag tacccgaggtgtcagggccg 
COX-2 NC000001.10 gcgagggccagctttcacca cctgccccacagcaaaccgt 
HMOX1 NM002133.2 cgtccgcaacccgacagcat cagccttgcggtgcagctct 
MCP-1 NM002982.3 agctcgcactctcgcctcca gcatctggctgagcgagccc 
IL10 NM000572.2 gctgcacccacttcccaggc gacagcgccgtagcctcagc 
iNOS NM000625.4 acccgagatggccagggtcc ccgcactcccttgtgctggg 
IL-1 NM000575.3 aatgacgccctcaatcaaag tgggtatctcaggcatctcc 
IL-4 BC067514.1 gccaccatgagaaggacact actctggttggcttccttca 
IFNγ BC070256 tgaccagagcatccaaaaga ctcttcgacctcgaaacagc 
2,3-IDO NM194294 ctggtcctgagcttcctcac cagcaccaagtctgagtgga 
HIF1 NM001530 tccatgtgaccatgaggaaa ccaagcaggtcataggtggt 
TNF HQ201306 agcccatgttgtagcaaacc tgaggtacaggccctctgat 
Actin NM001101.3 agcgggaaatcgtgcgtg cagggtacatggtggtgcc 
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HUVEC interactions. Briefly, 5x10
4
 PKH26-labeled HUVECs (Red) and 5x10
4 
PKH67-labeled 
pericytes (Green) were well mixed, resuspended in 700µl of EGM2, seeded onto Matrigel in a 
24-well plate, and further cultured for 24 hours. An in vitro 3D Matrigel culture system was used 
to investigate vascular support by pericytes. In short, 25x10
4
 pericytes were resuspended in 
EGM2 and well mixed with 350µl of Matrigel in a 3:1 ratio before being encapsulated into one 
well of a 24-well plate and subsequently incubated for 72 hours. A small amount of EGM2 was 
added after gelation and exchanged every 24-48 hours. Experiments using 25x10
4
 HUVECs 
were performed as controls. A 3D co-culture system using 25x10
4
 PKH26-labeled HUVECs 
(Red) and 25x10
4 
PKH67-labeled pericytes (Green) was performed in the same manner and 
subsequently cultured for 72 hours. All images were taken using an epi-fluorescence microscope 
(Nikon Eclipse TE 2000-U). 
3.2.13 Enzyme-linked immunosorbent assay (ELISA) 
The secretion of growth factors and cytokines in culture supernatant was quantified by enzyme-
linked immunosorbent assay (ELISA). Vascular endothelial growth factor (VEGF) secretion by 
microvascular pericytes was measured by human VEGF ELISA Kit (KHG0111, Invitrogen), 
following the manufacturer’s instructions. The secretion of angiopoietins-1 (Ang-1) and 
angiopoietins-2 (Ang-2) by pericytes was measured by human Ang-1 (DANG10, R&D) and 
Ang-2 (DANG20, R&D) ELISA Kits respectively, following the manufacturer’s instructions. 
Data are presented as pg/ml per 100,000 cells per 24 hours.   
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3.2.14 Measurement of cell proliferation 
Murine RAW264.7 monocyte/macrophage-like cells or primary muscle fibroblasts were 
quadruplicately plated (10
4
 cells/well) in a 96-well plate. Four hours later, the culture media were 
changed to normoxic or hypoxic pericyte-culture conditioned media, or fresh serum-free media 
for control wells. Cells were subsequently cultured under ambient conditions for 72 hours. At 
this time, wells were washed and CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay 
(MTS Assay) Reagent (G3582, Promega) in DMEM was added. The plate was incubated in 5% 
CO2 at 37 °C for 3 hours, at which point the absorbance at 490 nm was read with a 96-well plate 
reader.  
3.2.15 Statistical analysis 
All measured data are presented as mean ± standard error (SE). Kaplan-Meier survival 
curve estimation with log-rank test was performed to compare the animal survival rate between 
treatment groups. Statistical differences were analyzed by Student’s t-test (two groups), one-way 
ANOVA (multiple groups), or two-way repeated ANOVA (repeated measures) with 95% 
confidence interval. Student-Newman-Keuls multiple comparison test was performed for 
ANOVA post-hoc analysis. Statistical analyses were performed with SigmaStat 3.5 and SPSS19 
statistics software. 
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3.3 RESULTS 
3.3.1 Transplanted human pericytes s improve survival and cardiac function 
Cultured pericytes at passages 8-12 were characterized by flow cytometry (Figure 3 and Figure 4) 
and subsequently injected into the acutely infarcted myocardium of immunodeficient mice. 
Control groups received PBS injections or no injection (MI sham) following the induction of MI. 
The survival of animals receiving pericyte treatment (N=16) or no treatment (N=14) was 
monitored over the course of 8 weeks (Kaplan-Meier survival curve, Figure 5A).    
 
Figure 3: Morphology and characterization of purified pericytes in long-term culture 
Flow cytometry analysis revealed that cultured pericytes retain original cell surface marker expression, including the 
robust expression of CD146 and alkaline phosphatase (ALP) with the absence of CD34, CD45, and CD56. 
 
 50 
 
Figure 4: Flow cytometry analysis of MSC markers 
The results showed that long-term cultured pericytes strongly express classic MSC markers: CD90, CD44, CD73 
and CD105. 
 
Cardiac function was assessed by echocardiography performed repeatedly before (healthy) 
and at 2 and 8 weeks after surgery (Figure 5B). Ischemic hearts injected with pericytes isolated 
from two donors (designated as P1 and P2, N=8 per donor) had significantly smaller left 
ventricular (LV) chamber size, as measured by LV end-diastolic area (LVEDA, C) and end-
systolic area (LVESA, Figure 5D), than PBS control group (N=5) (all p<0.05), suggesting the 
reversal of progressive heart dilatation. The average LV chamber diastolic dimension after 
pericyte treatment (N=16) was significantly smaller when comparing to infarcted hearts without 
pericyte injection (N=10) (two-way repeated ANOVA, p=0.002). Moreover, pericyte-
transplantation groups displayed significantly better LV contraction, evaluated by LV fraction 
shortening (LVFS, Figure 5E) and LV fractional area change (LVFAC, Figure 5F), than either 
PBS (N=5) or MI sham (N=5) control groups at 2 and 8 weeks post-transplantation (all p<0.05). 
Collectively, pericyte treatment (N=16) demonstrated a significant therapeutic effect on LV 
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contractility when compared to sham treatment (N=10) (two-way repeated ANOVA, p<0.001). 
Echocardiographic parameters are documented in Table 4.  
 
Figure 5: Survival rate and cardiac functional assessment 
(A) Cumulative survival rate over 8 weeks post-surgery (Kaplan-Meier Survival Curve, log-rank test p=0.529). (B) 
Representative M-mode images of left ventricle (LV). End-systolic dimension (ESD) and end-diastolic dimension 
(EDD) were indicated. Echocardiographic analyses revealed a significant reduction of LV dilatation by 
transplantation of pericytes (P1 and P2), as shown by smaller LV areas in end-diastole (C) and end-systole (D) of 
hearts. Pericyte treatment also resulted in substantial improvement in LV contractility, as indicated by greater 
fractional shortening (E) and fractional area change (F). (†§p<0.05 versus PBS; *#p<0.05 versus PBS and MI sham) 
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Table 4: Echocardiographic parameters 
Pre- and post-MI NOD/SCID mouse hearts treated with or without pericytes. LV, left ventricle; ESD, end-systolic 
dimension; EDD, end-diastolic dimensions; ESA, end-systolic area; EDA, end-diastolic area; FS, fractional 
shortening; FAC, fractional Area Change. 
3.3.2 Transplanted pericytes promote host angiogenesis  
To explore the mechanisms exploited by pericytes to support functional cardiac recovery, we 
examined whether intramyocardial transplantation of pericytes benefits the host vascular network 
post-infarction. Capillaries in the peri-infarct areas (Figure 6A) and within the infarct region 
(Figure 6C) were revealed by anti-mouse CD31 (platelet endothelial cell adhesion molecule, 
PECAM-1) immunofluorescent staining. CD31-positive structures were quantified around and 
within the infarct region. Capillary density in the peri-infarct areas of pericyte-injected hearts 
(N=5) was increased by 42.8% when compared to saline-injected controls (N=5) (Figure 6B, 
P<0.05). Higher vascular density was also observed within the infarct region, with 33.2% more 
capillaries in the pericyte-treated hearts (Figure 6D, P<0.001). These findings suggest that 
transplanted pericytes promote host angiogenesis not only in the peri-infarct areas, where blood 
Group Healthy Pericyte treatment No treatment 
Time (Post-MI) Pre-MI 2 weeks 8 weeks 2 weeks 8 weeks 
LVESD (mm) 1.8±0.1 3.0±0.2 3.3±0.3 3.7±0.2 4.7±0.4 
LVEDD (mm) 3.4±0.2 4.2±0.2 4.5±0.3 4.5±0.2 5.4±0.4 
LVESA (mm
2
) 2.6±0.1 6.2±0.4 7.3±1.1 8.1±0.4 11.8±0.9 
LVEDA (mm
2
) 5.4±0.2 9.5±0.4 10.6±1.3 10.5±0.4 14.4±0.9 
LVFS (%) 44.7±1.2 28.2±2.3 25.3±2.1 17.5±2.0 13.4±1.1 
LVFAC (%) 50.9±0.4 34.5±2.0 32.4±2.8 22.9±1.4 18.5±1.7 
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vessels were generally better preserved after the ischemic injury, but also within the blood 
vessel-deprived infarct region. 
 
Figure 6: Promotion of host angiogenesis by pericyte treatment 
(A) Representative images of anti-mouse CD31 immunostaining in the peri-infarct area of hearts injected with 
pericytes or PBS. (B) Pericyte-treated hearts displayed a substantially higher capillary density in the peri-infarct area 
(*p<0.05). (C) Anti-mouse CD31 immunostaining within the infarct region. (D) Significantly higher capillary 
density within the infarct region of pericyte-transplanted hearts (*p<0.001). (Scale bars=50m) 
3.3.3 Engrafted pericytes home to perivascular locations 
It is not known whether transplanted pericytes home back to perivascular areas in vivo. To reveal 
their engraftment and homing pattern, cultured pericytes were transduced with a GFP reporter 
gene at near 100% efficiency (Figure 7A) and injected (3.0×10
5
 cells) into acutely infarcted 
hearts. GFP-labeled pericytes extensively engrafted throughout the host ventricular myocardium 
(Figure 7B), particularly in the peri-infarct area (Figure 7C). Confocal microscopy showed that 
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GFP-positive human pericytes can engraft the interstitial space where capillaries reside (Figure 
7D). A fraction of pericytes (white arrows) were identified in perivascular positions, in close 
contact with host CD31-positive endothelial cells (Figure 7D, inset). Indeed, pericytes were 
aligned with (Figure 7E) or surrounding (Figure 7E, inset) CD31-positive microvessels, 
suggestive of perivascular homing. The number of engrafted GFP(+) pericytes was 
approximately 9.1±1.3% of total injected cells at the first week and declined over time to 
3.4±0.5% at 8 weeks post-infarction (N=3 per time point) (Figure 7F, black line). The 
perivascular homing rate instead increased from 28.6% to 40.1% over the course of 8 weeks, 
implicating the merit of niche-homing for long-term donor cell survival (Figure 7F, red line). 
  
Figure 7: Transplanted pericytes home to perivascular locations 
(A) Pericytes were transduced with GFP reporter at nearly 100% efficiency (scale bar=200m). (B) Engraftment of 
GFP-labeled pericytes within host myocardium was revealed by anti-GFP immunostaining at 1 week post-injection 
(scale bar=500m, infarct site encircled by dotted lines). (C) Donor pericytes (stained red by anti-GFP) were 
particularly abundant in the peri-infarct area (scale bar=50m). (D) Confocal microscopy showed that pericytes can 
be located at the interstitial space where capillaries reside (scale bar=50m) with some GFP-positive cells (white 
arrows) in close contact with host CD31-positive endothelial cells ([D], inset; scale bar=10m). Pericytes were 
lining with (E, main) or surrounding ([E], inset) host CD31-positive microvasculature (scale bars=20m). (F) The 
engraftment ratio of pericytes at 1 week (9.1±1.3%) and 8 weeks (3.4±0.5%) post-infarction was depicted (dash-dot 
line). The perivascular homing ratio instead increased from 28.6% to 40.1% and was delineated (solid line). 
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3.3.4 Pericytes support microvascular structures 
To demonstrate that pericytes benefit host vascular networks through their support in 
microvascular structures, we developed 2D and 3D Matrigel cultures/co-cultures using pericytes 
and HUVECs. HUVECs seeded onto Matrigel-coated wells formed typical tubular networks 
after 24 hours (Figure 8A). Pericytes, however, formed similar structures within 6-12 hours of 
seeding (Figure 8B). To illustrate the cellular interaction between pericytes and HUVECs, dye-
labeled pericytes (PKH67, green) and HUVECs (PKH26, red) were mixed and co-cultured in 2D 
Matrigel, which resulted in the formation within 6-12 hours of capillary-like networks that 
included both cell types (Figure 8C). Pericytes (green) were observed to occupy peri-endothelial 
positions in the co-formed three-dimensional structures after incubation for 24 hours (Figure 8C, 
inlet). Additionally, HUVECs (red) appeared to align with pericytes (green) (Figure 8D). To 
further unveil the vascular supportive properties of pericytes, an in vitro 3D Matrigel system 
designed to simulate native capillary formation was used. HUVECs evenly distributed within the 
3D Matrigel were unable to form organized structures after 72 hours (Figure 8E). To the contrary, 
pericytes started to form capillary-like networks 24 hours after gel-casting, with structural 
remodeling over time (Figure 8F). The dynamic interaction between pericytes and HUVECs was 
best depicted by encapsulating dye-labeled pericytes (green) and HUVECs (red) in a 3D 
Matrigel plug. Together these two types of cells formed capillary-like networks after incubation 
for 72 hours (Figure 8G) with pericytes surrounding HUVECs (Figure 8H) These data suggest 
that pericytes retained vascular cell features and formed structures supportive of microvascular 
networks even after purification and long-term culture, while pericyte-EC interaction played a 
role in the pericyte-facilitated angiogenic process. 
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Figure 8: Pericytes support microvascular structures 
(A) While HUVECs seeded onto Matrigel-coated wells formed typical capillary-like networks after 24 hours, (B) 
pericytes formed similar structures within 6-12 hours (scale bars=1mm). (C) When co-cultured on Matrigel, dye-
labeled pericytes (green) and HUVECs (red) co-formed capillary-like networks within 6-12 hours, ([C], inset) with 
pericytes taking peri-endothelial positions in three-dimensional structures formed 24 hours after seeding (scale bars: 
main=200m; inset=100m). (D) HUVECs (red) appear to line and spread out on top of the pericyte-formed 
structures (green) (scale bar=100m). (E) To simulate native capillary formation, HUVECs were evenly 
encapsulated into 3D Matrigel plug for 72 hours but unable to form any organized structure (scale bars=1mm). (F) 
Pericytes instead formed capillary-like networks in Matrigel plug with structural organization and maturation over 
time (scale bars=1mm). (G) When dye-labeled pericytes (green) and HUVECs (red) were co-casted into the 3D-gel 
plug, the two types of cells formed microvessel-like networks within 72 hours, (H) with pericytes surrounding 
HUVECs (scale bars: G=200m; H=50m). 
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3.3.5 Differential expression of pro-angiogenic factors and associated receptors by 
pericytes under hypoxia 
We mimicked, at least in part, the hostile hypoxic microenvironment donor cells encounter in the 
post-infarction heart by culturing pericytes under 2.5% oxygen for 24 hours in defined, serum-
free medium. Pericytes cultured under 21% oxygen (normoxia) served as controls. Expression of 
genes encoding pro-angiogenic factors and corresponding receptors was assessed by real-time 
qPCR. Vascular endothelial growth factor-A (VEGF-A), platelet-derived growth factor-β 
(PDGF-β), and transforming growth factor (TGF)-β1 were notably up-regulated by 307% 
(p≤0.001), 437% (p=0.067), and 178% (p=0.037) respectively in pericytes cultured under 
hypoxic conditions (Figure 9A). Expression of other pro-angiogenic factors, including basic 
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and epidermal growth factor 
(EGF), was down-regulated to 44% (p<0.05), 23% (p≤0.001), and 60% (p>0.05) of their 
expression levels in normoxia (Figure 9A). On the other hand, VEGF receptor-1 (VEGFR-1/Flt-
1) and -2 (VEGFR-2/KDR/Flk-1) were substantially up-regulated by 458% (p=0.004) and 572% 
(p≤0.001) respectively under 2.5% oxygen (Figure 9B). PDGF receptor-β (PDGF-Rβ) expression 
was moderately increased by 161% (p>0.05) (Figure 9B). VEGF secretion by pericytes 
significantly increased over 3-fold (p≤0.001) under hypoxic culture conditions while 
angiopoietins-1 (Ang-1) secretion reduced by 35% (p>0.05) (Figure 9C). Very little secretion of 
angiopoietins-2 (Ang-2) by pericytes was detected under both conditions (p>0.05) (Figure 9C). 
The expression of human VEGF165 by engrafted pericytes within the infarct region was 
confirmed by immunohistochemistry (Figure 9D, a-c). 
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Figure 9: Expression of pro-angiogenic factors and associated receptors under hypoxia 
(A) Pericytes dramatically up-regulated VEGF-A, PDGF-β, TGF-β1 gene expression under hypoxic conditions 
while expression of other pro-angiogenic factors, including bFGF, HGF and EGF were distinctively repressed. (B) 
Simultaneously, VEGFR-1 (Flt-1) and -2 (Flk-1) were substantially up-regulated, and PDGF-Rβ expression was 
moderately increased. All expression levels are normalized to human cyclophilin and presented in arbitrary 
fluorescence units on an expanded logarithmic scale (#p<0.05, *p≤0.001, †p<0.01, hypoxic versus normoxic). (C) 
Significantly increased secretion of VEGF (p≤0.001) by pericytes under hypoxic culture conditions was detected by 
ELISA while the secretion of Ang-1 was reduced by 35% (p>0.05), with very little secretion of Ang-2 under both 
conditions (p>0.05). (D) Immunohistochemistry revealed human VEGF165 expression by the engrafted GFP-labelled 
pericytes within the infarct area at 2 weeks post-infarction (a) merge (b) GFP in green (c) hVEGF165 in red (scale 
bar=50m). 
3.3.6 Transplantation of pericytes reduces cardiac fibrosis  
To understand the influence of pericyte treatment on cardiac fibrosis, we evaluated scar tissue 
formation using Masson’s trichrome histological staining. At 2 weeks post-infarction, pericyte-
treated hearts displayed less collagen deposition (stained in blue/purple) at the ischemic area 
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(Figure 10A). Estimation of the total fibrotic tissue ratio unveiled a 45.3% reduction of cardiac 
fibrosis in the pericyte-injected myocardium (N=5, 22.03±1.81%) when comparing to saline-
injected controls (N=5, 40.28±2.15%) (Figure 10B, p≤0.001), suggesting the anti-fibrotic 
efficacy of pericytes. Measurement of LV wall thickness at the center of the infarct indicated a 
26.3% increase in the pericyte group (0.255±0.026 mm) versus the PBS group (0.202±0.040 
mm), suggesting that pericytes reduce transmural infarct thinning following MI, and 
consequently preserve LV wall thickness (Figure 10C, p>0.05). 
3.3.7 Paracrine anti-fibrotic effects of pericytes under hypoxia 
To elucidate the mechanism(s) involved in pericyte-mediated reduction of fibrosis, we performed 
a cell proliferation assay using murine primary muscle fibroblasts cultured with pericyte-
conditioned medium. Fibroblast proliferation was significantly reduced when cultured in hypoxic 
pericyte-conditioned medium, compared to normoxic controls (Figure 10D, p=0.011), suggesting 
a paracrine anti-fibrotic effect by pericytes in hypoxia. We further proposed a fibrolytic role of 
pericyte-derived matrix metalloproteinases (MMPs) and examined gene expression of MMP-2 
and MMP-9 by real-time qPCR. Cultured pericytes expressed more MMP-2 but nearly 10 times 
less MMP-9 than total skeletal muscle lysates (tissue origin control) (Figure 10E). We then 
explored MMP expression in hypoxia-cultured pericytes and demonstrated that MMP-2 
expression in pericytes was well sustained under 2.5% oxygen, compared to normoxic culture 
(Figure 10F, p>0.05), while MMP-9 expression remained extremely low without significant 
change (Figure 10F, p>0.05).  
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Figure 10: Attenuation of myocardial fibrosis by pericyte-treatment 
(A) Masson’s trichrome-stained transverse sections of hearts injected with pericytes or PBS (collagen in blue/purple, 
cardiac muscle in red) (scale bars=1 mm). (B) The fibrotic area fraction was dramatically decreased in pericyte-
injected hearts (p≤0.001). (C) Pericyte group had a non-significant increase in the infarct wall thickness. (D) The 
proliferation of murine muscle fibroblasts was significantly reduced when culturing with hypoxic pericyte-
conditioned medium (*p=0.011, versus normoxic pericyte-conditioned medium). (E) Expression of MMP-2 in 
cultured pericytes was higher than that in skeletal muscle lysates. Conversely, MMP-9 expression in pericytes was 
nearly 10 times less (logarithmic scale of 10 in arbitrary fluorescence units). (F) Expression of both MMP-2 and -9 
in pericytes did not change significantly under hypoxia (p>0.05, logarithmic scale of 10 in arbitrary fluorescence 
units).  
3.3.8 Transplantation of pericytes inhibits chronic inflammation 
Histological analysis of pericyte- and PBS-injected hearts after hematoxylin and eosin (H&E) 
staining indicated an increased focal infiltration of inflammatory cells (cluster of cells with dark 
blue-stained nuclei) within the infarct region in the latter (Figure 11A). To more precisely 
evaluate the immunomodulatory effect of pericyte transplantation, we detected host CD68-
positive monocytes/macrophages by immunohistochemistry. Pericyte-injected hearts exhibited 
diminished infiltration of host phagocytic cells within the infarct region at 2 weeks post-
infarction (Figure 11B). Districts of the myocardium unaffected by the ischemic insult (posterior 
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and septal walls) contained few CD68-positive cells in either group, similar to healthy hearts 
(Figure 11C). Quantitatively, injection of pericytes (N=5) resulted in a 34% reduction in 
infiltration of CD68-positive cells at 2 weeks post-infarction when compared to PBS controls 
(N=5) (Figure 11D, p<0.001). 
3.3.9 Paracrine immunomodulation by pericytes 
To understand the underlying mechanism of pericyte-induced inhibition of phagocytic cell 
infiltration, we analyzed the proliferation of murine monocytes/macrophages cultured with 
pericyte-conditioned medium. Cell proliferation assays revealed that murine 
monocyte/macrophage proliferation was significantly inhibited when culturing with normoxic 
(p=0.018) and hypoxic (p<0.001) pericyte-conditioned media, compared to control medium 
(Figure 11E). Furthermore, hypoxic pericyte-conditioned medium exhibited a more prominent 
immunomodulatory effect than the normoxic counterpart (Figure 11E, p=0.002). To shed light 
on the molecules accountable for this paracrine immunomodulation, we investigated by sqRT-
PCR the differential expression by pericytes cultured under normoxia or hypoxia of genes 
implicated in immunoregulation. In either condition, pericytes indeed expressed a considerable 
array of anti-inflammatory cytokines: IL-6, LIF, cyclooxygenase-2 (COX-2/PTGS-2, 
prostaglandin endoperoxide synthase-2) and HMOX-1 (Figure 11F). Similarly, monocyte 
chemotactic protein-1 (MCP-1) and hypoxia-inducible factor-1 (HIF-1) were highly 
expressed by pericytes (Figure 11F). Conversely, we detected very low to no expression by 
pericytes of pro-inflammatory cytokines including interleukin-1 (IL-1), tumor necrosis factor-
 (TNF-), and interferon-γ (IFNγ) as well as no expression of interleukin-4 (IL-4), interleukin-
10 (IL-10), inducible nitric oxide synthase (iNOS), or indoleamine 2,3-dioxygenase (2,3-IDO) 
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(Figure 11F). Quantitatively, there was no significant alteration of expression under hypoxia of 
immunoregulatory genes investigated, except MCP-1, whose expression was notably decreased 
in hypoxia-cultured pericytes (Figure 11G, all p>0.05; MCP-1, p=0.027). 
 
Figure 11: Reduction of host phagocytic cell infiltration by pericyte transplantation 
(A) H&E staining revealed a greater focal infiltration of leukocytes (dark blue-stained nuclei) within the infarct 
region in PBS-injected controls at 2 weeks post-infarction (scale bars=100m). (B) Anti-mouse CD68 
immunostaining showed that the infarct region of pericyte-injected hearts contains less host phagocytic cells (scale 
bars=50m). (C) Host CD68-positive cells were locally attracted to the infarct region but not to the unaffected 
myocardium (posterior ventricular wall) in both groups (scale bars=50m). (D) Host monocytes/macrophage 
infiltration at the infarct site was significantly reduced (p<0.001). (E) The proliferation of murine macrophages was 
significantly inhibited when culturing with pericyte-conditioned media (
＊
p=0.018, 
#
p<0.001, versus control 
medium), an effect more prominent with hypoxic pericyte-conditioned medium (
†
p=0.002, hypoxia versus 
normoxia). (F) Cultured pericytes exhibited sustained, high expression of genes regulating the inflammatory 
responses, even under 2.5% O2 (N: normoxia; H: hypoxia). Little expression of IL-1 and no expression of IL-4, IL-
10, iNOS, 2,3-IDO, TNF-, and IFNγ were detected. (G) No statistically significant difference in expression of 
genes of immunoregulatory molecules between normoxic- and hypoxic-cultured pericytes except MCP-1, which 
notably decreased in hypoxic cultures (sqRT-PCR analysis, p=0.027). 
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3.3.10 Cell lineage fate of transplanted pericytes 
GFP-labeled pericytes were employed to track cell lineages developed from engrafted pericytes 
and investigate the capacity of human muscle pericytes to reconstitute major cardiac cell types 
after injury. Immunohistochemistry was performed to simultaneously detect GFP and cell lineage 
markers: the cardiomyocyte marker, cardiac troponin-I (cTn-I); the smooth muscle cell (SMC) 
marker, smooth muscle myosin heavy chain (SM-MHC); the endothelial cell (EC) marker, CD31. 
Confocal microscopy revealed that in the peri-infarct area, a minor fraction of engrafted 
pericytes co-express GFP and cTn-I (Figure 12A), a few of which appear single-nucleated 
(Figure 12A, inset). Some GFP-positive cardiomyocytes were identified within the remaining 
myocardium (Figure 12B) with organized sarcomeric patterns (Figure 12C). A very small 
number of engrafted pericytes co-expressed GFP and human-specific CD31 (<1%) (Figure 12D-
F). Similarly, co-expression of GFP and human-specific SM-MHC was detected in very few 
donor cells (<0.5%) (Figure 12G-I). 
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Figure 12: Tracking the cell lineage fate of engrafted pericytes 
Confocal microscopy revealed that in the peri-infarct area (A) a minor fraction of GFP-labeled pericytes co-
expressed a mature cardiomyocyte marker, cardiac troponin-I (cTn-I) ([A], main, scale bar=50m); a few of them 
appear single-nucleated ([A], inset, scale bar=10m) (cTn-I in red, Anti-GFP in green). (B) Immunofluorescent 
detection of GFP-cTn-I dual-positive cardiomyocytes integrating within the residual myocardium (scale bar=50m) 
with dotted area enlarged in (C) showing sarcomeric patterns (scale bar=20m). (D-F) A very small number of 
GFP(+) pericytes (<1%) co-expressed human-specific CD31 (hCD31 in red, Anti-GFP in green; scale bar=10m). 
(G-I) Few donor pericytes (<0.5%) expressed human-specific SM-MHC (hSM-MHC in red, Anti-GFP in green; 
scale bar=10m).  
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3.4 DISCUSSION 
Pericytes constitute a major structural component of small blood vessels, regulating vascular 
development, integrity and physiology. The recent identification of microvascular pericytes as 
native MSC ancestors raised the possibility that these cells participate in the repair of 
injured/ageing organs[26, 46, 47, 53, 61-63, 112, 113]. Structural and functional regeneration of 
skeletal muscle involving direct pericyte differentiation into regenerative units as well as 
potential applications in lung repair and vascular tissue engineering indicate the therapeutic 
potency of pericytes[26, 46, 53, 54, 112]. Pericytes can also repair tissue via secretion of trophic 
and immunomodulating factors, implying a greater curative potential in clinical settings [17, 
112]. The increased proliferation and migration of pericytes in response to low oxygen 
concentration and ECM degradation products have important implications for ischemic injury 
repair[114].  
Recent studies indicated a possible developmental hierarchy among different 
stem/progenitor cell populations residing in blood vessel walls [39, 47]. Katare et al. reported 
that transplantation of adventitial pericyte progenitor cells repairs infarcted hearts through 
angiogenesis involving microRNA-132 [56]. Herein we demonstrate that transplantation of 
human FACS-purified microvascular pericytes contributes to the functional and structural repair 
of the ischemic heart, albeit unequally, through both of the aforementioned restorative pathways. 
A major goal of SCCT, the prevention of progressive LV dilatation and consequent heart failure, 
was largely achieved by pericyte treatment, implicating the attenuation of deleterious remodeling. 
We also observed significant improvement of cardiac contractility in an acute infarction milieu, 
with up to 70% of healthy contractile function consistently maintained for at least two months. 
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No significant difference was observed between adult and fetal pericytes in terms of heart repair. 
The therapeutic benefits observed could be explained, at least in part, by angiogenic, anti-fibrotic, 
anti-inflammatory, and to a lesser extent, cardiomyogenic properties of pericytes. 
A linear correlation between secretion of pro-angiogenic factors, angiogenesis and 
cardiac restoration was illustrated by blocking VEGF bioactivity from administered murine 
muscle-derived stem cells, which not only abolished their stimulation of neovascularization but 
negatively influenced LV contractility and infarct size [84]. Okada et al. further delineated the 
superior angiogenic properties of human myoendothelial progenitor cells and secretion of VEGF 
in response to hypoxia [52]. Given the indigenous vascular association of pericytes, we 
hypothesized that pericytes are able to repair the damaged microvasculature. Indeed, upon 
pericyte treatment, we observed a significantly larger host microvascular network not only in the 
peri-infarct collateral circulation but within the infarct region itself. Cultured pericytes secrete 
growth factors/cytokines/chemokines related to vascular physiology and remodeling [17]; among 
which, only VEGF-A, PDGF-β, and TGF-β1 were substantially up-regulated under hypoxia, 
suggesting their role in pericyte-enhanced angiogenesis [86, 126]. 
Angiogenesis, and possibly vasculogenesis, may follow cell-cell contact between donor 
pericytes and host endothelial cells (ECs), in addition to stimulation by angiogenic factors. 
Recent studies reported that MSCs and vascular mural/adventitial cells support ECs in small 
blood vessel formation and maturation in culture and in vivo [40, 118]. We did observe the 
perivascular homing of donor pericytes in the ischemic heart. Planar Matrigel culture confirmed 
the vascular cell characteristics of pericytes and their capability to interact with ECs. We further 
demonstrated microvessel formation and vascular support by pericytes in three-dimensional 
cultures, indicating that interaction between pericytes and ECs may contribute to 
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revascularization. Altogether, these results demonstrate that the angiogenic properties of 
pericytes may result from both indirect paracrine effects and direct cellular interactions.  
The anti-fibrotic action of mesodermal stem/progenitor cells in the injured heart has been 
widely reported [121-123]. MSC-conditioned medium diminished viability, proliferation, 
collagen synthesis and α-SMA expression in cardiac fibroblasts but stimulated MMP2/9 
activities, indicating a paracrine anti-fibrotic property of MSCs [122, 123]. Our results 
demonstrated a near 50% reduction of myocardial fibrosis and a trend to abate thinning of the 
infarcted myocardial wall following pericyte injection. Along with the attenuation of progressive 
LV dilatation, pericyte treatment appears to result in propitious remodeling, leading to improved 
myocardial compliance and strengthening of ischemic cardiac tissue.  
We speculated that decreased scar formation is, at least partially, associated with a 
reduced number of fibrotic cells resulting from the administration of pericytes. Interestingly, 
pericyte-treated hearts contained significantly less cells within the infarct area than saline-
injected controls (p<0.05, Figure 13). Due to the highly fibrotic nature of MI, we were unable to 
quantitate fibrotic cells in vivo. Nevertheless, murine muscle fibroblast proliferation was notably 
inhibited when cultured in hypoxic pericyte-conditioned medium in vitro, indicating the 
paracrine fibrosuppressive effect of pericytes under hypoxia. Matrix metalloproteinases (MMPs)  
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Figure 13: Comparison of total cell density within the infarct area 
Pericyte-injected hearts at 2 weeks post-infarction had a significantly less number of cells within the infarct area 
than the saline-injected controls (P<0.05). 
were suggested to play important roles in post-injury scar remodeling, angiogenesis, and vascular 
cell proliferation/migration [123, 126]. In particular, a preponderant role of MMP-2 in 
preventing collagen accumulation by cardiac fibroblasts was proposed [123]. Consequently, we 
postulated the existence of a fibrolytic activity from donor pericytes, involving MMPs, which 
contributes to the attenuation of cardiac fibrosis. Indeed, high expression of MMP-2, but not 
MMP-9, by pericytes, even under hypoxic conditions, was observed, implicating a role for 
MMP-2 in pericyte-mediated amelioration of fibrosis.  
The immunosuppressive potential of MSCs, demonstrated by inhibiting T-lymphocyte 
proliferation in culture and counteracting graft-versus-host reaction in recipients of allogeneic 
blood stem cells, is currently exploited in clinical trials [124, 125]. In the cardiac milieu, MSC 
transplantation in a rat model of acute myocarditis mitigated the increase in CD68+ phagocytic 
cells [127]. In the present study, pericyte treatment significantly diminished host 
monocyte/macrophage infiltration in the infarcted myocardium, suggesting an anti-inflammatory 
potential which contributed to the reduction of fibrosis, amelioration of adverse remodeling, and 
improvement of cardiac function. Nevertheless, whether pericytes inhibit the acute-phase 
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inflammation occurring soon after the incidence of MI is unknown. Inhibition of murine 
monocyte/macrophage proliferation in culture by pericyte-conditioned medium suggests a 
paracrine mechanism of their immunomodulatory capacity. 
The immunosuppressive and anti-inflammatory capacities of MSCs are primarily 
attributed to soluble factors/molecules, as IL-6, LIF, and HMOX-1 were shown to exercise 
beneficial immunosuppressive effects [124, 125]. The attenuation by MSCs of intense 
inflammation and mitigation by the same cells of multi-organ damage is dependent on 
monocyte/macrophage-derived cytokines and regulated via PGE2 signaling [128]. The 
immunoregulatory and cardioprotective functions of these molecules appear to be similar in the 
cardiac milieu [119, 129]. Our data demonstrate that pericytes express high levels of IL-6, LIF, 
COX-2, HMOX-1, and HIF-1, which are sustained under hypoxic conditions. MCP-1 
expression, however, notably decreased under hypoxia, corresponding with reduced CD68+ cell 
infiltration in vivo. Little to no expression of pro-inflammatory cytokines including IL-1, TNF-
 and IFNγ was observed. Virtually no expression of IL-4, IL-10, iNOS, and 2,3-IDO was 
detected in pericytes, suggestive of an immunoregulatory cytokine secretome that is unique to 
human microvascular pericytes [125, 130]. Intriguingly, TGF-β1, also an anti-inflammatory yet 
fibrogenic cytokine, was strongly expressed by pericytes [119, 131]. Given the multiple 
functions each proposed growth factor/cytokine possesses, it is likely that a dynamic, interactive, 
and intricately orchestrated balance of trophic factors between donor and host cells holds the key 
to a successful ischemic tissue remodeling and regeneration. 
The potential of human muscle pericytes to reconstitute major cell types in the injured 
myocardium, though to a small extent, was hereby demonstrated. Cell fate tracking suggests that 
a minor fraction of engrafted pericytes differentiated into and/or fused with cardiomyocytes. 
 70 
Given the small number of GFP-cTnI dual-positive cells present, it is unlikely that these 
differentiated cells contributed significantly to functional recovery [85]. Pericytes, all of which 
were α-SMA-positive during culture expansion, lost α-SMA expression once homing to host 
microvasculature (data not shown), consistent with our finding that a subset of native 
microvascular pericytes do not express α-SMA in situ [26]. 
3.5 CONCLUSION 
In summary, purified human microvascular pericytes contribute to anatomic and functional 
cardiac improvement post-infarction through multiple cardioprotective mechanisms: reverse of 
ventricular remodeling, promotion of host angiogenesis, reduction of cardiac fibrosis, and 
diminution of chronic inflammation. Vessel-homing and small-scale regenerative events by 
pericytes partially reconstitute lost cardiac cells and contribute to the structural recovery. These 
cardioprotective and cardioregenerative activities of a novel stem cell population that can be 
purified to homogeneity and expanded in vitro await further research and exploitation in 
ischemic cardiovascular diseases. Due to the extensive local inflammatory response and tissue 
adhesion resulted from myocardial and infarction open-chest surgery, it is technically more 
difficult to handle and process samples harvested at 8 weeks post-surgery for histological 
examination. I am currently improving my surgical techniques to overcome this deficit. 
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4.0  HUMAN HEART PERICYTES: MULTIPOTENT MESODERMAL 
PROGENITORS WITHIN THE MYOCARDIUM EXHIBITING TISSUE SPECIFICITY 
4.1 INTRODUCTION 
The human heart has long been considered a terminally differentiated organ with no regenerative 
capacity [108]. However, recent discoveries of resident cardiac stem/progenitor cells as well as 
active cardiomyocyte turnover throughout the adult human life raise the possibility that the 
human heart has an innate yet restricted regenerative potential [96, 132-135]. In fact, the heart is 
a complex organ comprising a variety of muscle and non-muscle cells, including cardiac and 
smooth muscle, endothelial, stromal/interstitial, valvular, and pacemaker/conduction cell types 
with discrete contractile, vascular, structural, and electrical roles [18, 108]. Collaborative efforts 
from multiple cell types operating in a temporally and spatially coordinated fashion may hold the 
key for successful regeneration of functional cardiac tissue [18]. It is therefore important to 
apprehend the significance of subpopulations of non-muscle cells in physiological and 
pathological cardiac regeneration. 
Microvascular mural cells, i.e. pericytes, tightly surround capillaries and microvessels 
and play significant roles in vascular development, physiology and structural integrity [30, 136]. 
The essential function of pericytes to recruit and stabilize endothelial cells (ECs) is critical to the 
success of angiogenesis during the maturation and remodeling phase [30, 136]. We and others 
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have recently shown that pericytes purified from a number of human organs, such as skeletal 
muscle, adipose, placenta, umbilical cord, and pancreas, possess multi-lineage differentiation 
potential and stem/progenitor cell features [17, 26, 46, 53, 113, 137]. Pericytes regenerate injured 
and dystrophic skeletal muscles efficiently in murine models, showing great promise in 
regenerative medicine [26, 46, 53, 113]. Additionally, several populations of tissue-specific 
precursor cells have also been associated with the perivascular niche, indicating the important 
roles of vascular mural cells in tissue turnover and regeneration [9, 61, 106]. Nevertheless, it 
remains to be tested whether native cardiac pericytes exhibit the same phenotypes and 
mesodermal multipotency as their counterparts in other tissue. Furthermore, their putative roles 
in cardiac repair/regeneration and potential relationship to resident cardiac stem/progenitor cells 
await exploration. 
Another important question yet to be answered is whether all pericytes are born equal. It 
has been shown that the pericyte population appears to be highly variable physiologically among 
different organs and tissues, possibly reflecting their roles in regulating hydrostatic pressures and 
vascular homeostasis [138]. However, due to the difficulty to purify multiple pericyte 
populations from different tissue sources simultaneously, it remains unknown if any tissue 
specificity exists in terms of multipotency and/or distinct cellular behaviors in response to 
pathological conditions.  
In this study, we reported the identification, prospective purification, and characterization 
of resident heart pericytes (HPs). We described their cellular phenotypes, behaviors, and 
multipotency in long-term culture. By comparing HPs with skeletal muscle-derived pericytes 
(SkMPs), we investigated the possibility that tissue specificity and/or differential responses to 
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pathophysiological conditions exist among pericytes of developmentally and functionally 
different origins. 
4.2 METHODS AND MATERIALS 
4.2.1 Human tissue biopsies 
In total, 4 adult and 16 fetal human heart specimens were independently used for 
immunohistochemistry and cell isolation. Human adult cardiac biopsies were obtained at 
postmortem from subjects that had died from non-cardiac causes. The usage of adult cardiac 
tissue was approved by Tayside Committee on Medical Research Ethics, NHS Scotland. Human 
fetal tissues (17 to 23 weeks of gestation) were obtained following voluntary or therapeutic 
pregnancy interruptions performed at Magee Womens Hospital of UPMC, in compliance with 
IRB protocol 0506176. Developmental age was estimated by measuring foot length. Informed 
consent for the use of human fetal tissues was obtained from patients in all instances.  
4.2.2 Cell isolation 
Fresh human adult and fetal cardiac tissues were processed for the cell isolation. Briefly, atria, 
heart valves, and major blood vessels were grossly removed, followed by microscopic removal 
of pericardium and endocardium from the ventricles. Ventricular myocardium was first cut into 
small pieces in Dulbecco’s modified Eagle medium (DMEM, Invitrogen) containing 10% fetal 
bovine serum (FBS, Invitrogen), 1% penicillin-streptomycin (PS, Invitrogen), mechanically 
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minced, and subsequently digested with collagenases I, II and IV (1 mg/mL, Sigma) for 15-20 
minutes, depending on the sample size, under agitation at 37
°
C. After centrifugation, pellets were 
washed and resuspended in erythrocyte lysis buffer (155 mM NH4Cl, 10mM KHCO3, 0,1mM 
EDTA) and incubated for 10 min at room temperature (RT). Cells were then washed and 
sequentially filtered through 100- and 70-μm cell strainers (BD Falcon) to obtain single cell 
suspension. Fresh human fetal muscle biopsies obtained from the same donor were processed for 
the cell isolation according to the previously published protocol.  
4.2.3 Fluorescence-activated cell sorting (FACS) and flow cytometry analysis 
4.2.3.1 Cell sorting 
For cell sorting, cells (2-5x10
6
) were incubated with all of the following fluorochrome-
conjugated mouse anti-human antibodies (all with 1:100 dilutions): anti-CD34-APC (Becton-
Dickinson), anti-CD45-APC-Cy7 (Santa Cruz), anti-CD56-PE-Cy7, anti-CD117-PE, and anti-
CD146-FITC (all from Serotec) in DMEM supplemented with 5% FBS and 1% PS at 4ºC for 20 
min in the dark. As negative controls, isotype-matched mouse IgGs conjugated with APC, PE-
Cy7 (both from Becton-Dickinson), APC-Cy7 (Santa Cruz), PE and FITC (both from Chemicon), 
were used. After washing, all labelled cells were incubated with 7-amino-actinomycin D (7-AAD) 
(Becton-Dickinson, 1:100) for dead cell exclusion and then sorted on a FACSAria flow 
cytometer (Becton-Dickinson). Purified HPs (CD146
high
CD34
-
CD45
-
CD56
-
CD117
-
) were 
collected for culturing. Skeletal muscle-derived pericytes (SkMPs) were sorted according to the 
previously published protocol. 
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4.2.3.2 Flow cytometry analysis 
Flow cytometry was employed to examine the expression profile of cell lineage markers. Briefly, 
freshly sorted HPs or cultured HPs at different passages were labelled with the following 
fluorochrome-conjugated antibodies (all with 1:100 dilutions): anti-CD34-APC, anti-CD44-PE, 
anti-CD90-APC, anti-CD146-PE, anti-platelet-derived growth factor receptor-β (PDGFRβ)-PE 
(all from Becton-Dickinson), anti-CD73-PE, anti-CD105-PE (both from Invitrogen), anti-CD45-
APC-Cy7 (Santa Cruz), anti-CD56-PE-Cy7, anti-CD117-PE, and anti-CD146-FITC (all from 
Serotec), for 20 min at 4ºC and subsequently analyzed on a FACSAria flow cytometer.  
4.2.4 Cell culture and cell labelling 
4.2.4.1 Cell culture 
Freshly sorted HPs were initially seeded at 2x10
4
 cells/cm
2
 in endothelial cell growth medium 2 
(EGM-2
TM
, Lonza) and cultured at 37ºC for 2 weeks in plates coated with 0.2% gelatin 
(Calbiochem) until confluence. HPs were then detached by 0.25% trypsin-EDTA treatment 
(Invitrogen) for 10 min at 37ºC, split at 1:3 in uncoated plates in DMEM high glucose 
(Invitrogen) supplemented with 20% FBS and 1% PS. After the third passage, cells were 
passaged 1:5-1:6 and maintained in the same conditions with culture medium changed every 3-4 
days. We calculated the population doubling time (PDT) as previously described. Sorted SkMPs 
were expanded and maintained in the same conditions as HPs. Single donor-derived human 
umbilical cord vein endothelial cells (HUVECs) were purchased from Lonza and cultured in 
EGM-2
TM
, following the manufacturer’s instructions.  
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4.2.4.2 Cell labelling 
For the gene transfer of green fluorescence protein (GFP), cultured HPs at passages 5-7 were 
detached with trypsin-EDTA and seeded at a density of 10,000 cells/cm
2
.
 
After 24-48 hours, 
medium was replaced with the transduction medium (α-MEM, 10% FBS, 1% P/S, and 8 g/mL 
polybrene) when the culture was reaching 60-70% confluence, and a lentivirus-based CMV-
driven eGFP expression vector
 
was added at a MOI of 10. Following incubation for 16-18 hours 
at 37ºC, the transduction medium was removed and replenished by complete culture medium. 
Three days later, nearly 100% of cells expressed GFP. GFP-labeled cells were further expanded 
in regular culture medium for 1-2 passages without significant adverse effect. For short-term in 
vitro experiments, cells were labelled with cell membrane dye, PKH26 (Red) and PKH67 (Green) 
(both from Sigma-Aldrich), following the manufacturer’s instructions. Dye-labelled cells were 
applied to experiments immediately after labelling without further expansion.  
4.2.5 Immunohistochemical and immunocytochemical analyses 
Sections were fixed in a pre-cooled (-20°C) mixture of methanol (Fisher Scientific) and acetone 
(VWR International) (1:1) for 5 min or in pre-cooled acetone for 5 min (for human spectrin) 
prior to staining. For immunocytochemistry, cultured HPs were washed twice with PBS and 
fixed in a pre-cooled methanol for 5 min. Non-specific antibody binding was blocked with 5% 
donkey or goat serum for 1 hour at room temperature (RT) and, if necessary, with the Mouse-on-
Mouse (M.O.M.) antibody staining kit (Vector Laboratories). The following uncoupled primary 
antibodies were used: mouse anti-human CD31 (Santa Cruz), CD144 (Beckman Coulter), 
chondroitin sulphate (NG2), CD34, CD146 (all from Becton-Dickinson), and PDGFRβ (R&D 
Systems) (all at 1:100 dilutions); CD44, CD90 (both from Becton-Dickinson), CD73, CD105 
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(both from Invitrogen), and smooth muscle-myosin heavy chain (DAKO) (all at 1:50 dilutions) 
at 4ºC overnight. The following coupled primary antibodies were used: anti-mammalian alpha-
smooth muscle actin (αSMA)-FITC (Sigma-Aldrich) and von Willebrand factor (vWF) (US 
Biological), biotinylated anti-human CD144 (Becton-Dickinson) (all at 1:100 dilutions), 
biotinylated anti-human CD146 (Miltenyi Biotec, 1:20). Skeletal muscle proteins were detected 
with anti- fast skeletal myosin heavy chain, anti-slow skeletal myosin heavy chain, anti-desmin 
(all from Sigma-Aldrich), anti-spectrin (Novocastra) (all at 1:100 dilutions). Directly biotinylated 
Ulex europaeus lectin (UEA-1) was also used as an endothelial cell marker (Vector Laboratories, 
1:200). 
After rinsing with PBS three times, sections were incubated for 1 hour at RT with a 
fluorochrome-conjugated secondary antibody at 1:400 dilutions, including anti-mouse 
Alexa
TM
488 IgG, and anti-mouse-Alexa
TM
555 IgG (both from Molecular Probes); or with 
biotinylated secondary antibody and then with fluorochrome-coupled streptavidin (both at 1:500 
dilutions), including goat anti-mouse biotinylated  IgG antibodies (DAKO and Immunotech), 
Streptavidin-Cy3 (Sigma-Aldrich), and Streptavidin-Cy5 (CyDye); all diluted in 5% donkey or 
goat serum in PBS. Nuclei were stained with DAPI (4’, 6-diamino-2-phenylindole 
dihydrochloride, Molecular Probes, 1:2000) for 5 min at RT. An isotype-matched negative 
control was performed with each immunostaining. Slides were mounted in glycerol-PBS (1:1, 
Sigma) and observed on an epifluorescence microscope (Nikon Eclipse TE 2000-U). 
Alternatively, sections were analyzed on an Olympus Fluoview 1000 confocal microscope 
equipped with 100X oil immersion optics.  
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4.2.6 Multi-lineage differentiation in culture  
4.2.6.1 Osteogenesis  
For in vitro bone formation, cells at 70% confluence were cultivated in DMEM supplemented 
with 10% FBS, 0.1µM dexamethasone, 50µg/mL L-ascorbic acid, and 10mM beta-
glycerophosphate. Three weeks later, cells were fixed in 4% formaldehyde for 2 min and 
incubated for 10 min with alizarin red, pH 4.2 for the detection of calcium deposits (all reagents 
from Sigma-Aldrich).  
4.2.6.2 Chondrogenesis 
Pellet culture was performed by spinning down 3x10
5
 cultured cells in each 15ml conical tube 
(BD Falcon) and grown in serum-free DMEM containing an insulin-transferrin-selenious acid 
mix (ITS) (Becton-Dickinson), 50µg/ml L-ascorbic acid 2-phosphate (WAKO), 100µg/ml 
sodium pyruvate, 40µg/ml L-proline (both from Invitrogen), 0.1µM dexamethasone (Sigma-
Aldrich) and 10ng/ml transforming growth factor β1 (TGF-β1; Peprotech). Three weeks later, 
pellets were fixed in 10% formalin, dehydrated in ethanol and embedded in paraffin. Sections 
(5µm thick) were rehydrated and stained with Alcian blue and nuclear fast red for the detection 
of sulfated glycosaminoglycans and nuclei, respectively. 
4.2.6.3 Adipogenesis 
Cultured cells at 70% confluence were switched to adipogenic medium: DMEM containing 10% 
FBS, 1µM dexamethasone, 0.5µM isobutylmethylxanthine, 60µM indomethacine, and 170µM 
insulin (all from Sigma-Aldrich). Two weeks later, cells were fixed in 2% PFA at RT, washed in 
60% isopropanol and incubated with Oil red O for 10 min at RT for the detection of lipids.  
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4.2.6.4 Skeletal myogenesis 
Cells (2x10
3 
cells/cm
2
) were cultured for 7 days in muscle proliferation medium: DMEM high-
glucose supplemented with 10% FBS, 10% horse serum (HS, Invitrogen), 1% chicken embryo 
extract (CEE, Accurate), and 1% PS, and then for additional 7 to 10 days in muscle fusion 
medium: DMEM high-glucose supplemented with 1% FBS, 1% HS, 0.5% CEE, and 1% PS. 
Half of the medium was renewed every 3-4 days. Skeletal myogenesis was induced by lowering 
total serum concentration from 20% to 2% until elongated, multinucleated skeletal myofibers 
appeared. 
4.2.6.5 Cardiomyogenesis 
Cultured pericytes were seeded at 2x10
3 
cells/cm
2
 and further cultured for 1-2 days in pericyte 
medium. The medium was then replaced with cardiomyogenic induction medium: DMEM high-
glucose supplemented with 5% FBS, 1% PS, and 10µM 5-azacytidine for 72 hours. After 
washing, cells were cultured in pericyte medium for additional 2 weeks. 
4.2.7 Myogenesis in vivo 
To examine myogenesis of human heart pericytes in vivo, we performed cell transplantation in 
an immunodeficient murine muscle injury model. The Institutional Animal Care and Use 
Committee at Children’s Hospital of Pittsburgh of UPMC and University of Pittsburgh approved 
the animal usage and surgical procedures performed in this study (Protocol 15-04 and 0810310). 
A Total of 8 female SCID-NOD mice (4-6 weeks old) (Jackson Laboratory, Bar harbor, ME, 
USA) were used for this study.  
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 Briefly, SCID-NOD mice were anaesthetized by inhalation of isoflurane/O2. 
Cardiotoxin (CTX, 15 μg, Molecular Probes), diluted in 20 μL PBS, was injected into the 
gastrocnemius muscle three hours prior to cell transplantation. Mice were re-anaesthetized, and 
5.0×10
4 cells suspended in 30 μL PBS (or the same volume of PBS as a control) were slowly 
injected into the injured muscle. Mice were sacrificed 2 weeks later, and muscle was flash frozen 
in in 2-methylbutane (Sigma-Aldrich) pre-cooled in liquid nitrogen and embedded in tissue 
freezing medium (Triangle Biomedical Sciences). Samples were preserved at -80°C and 
cryosectioned at 8-10 µm thickness. 
4.2.8 Hypoxia assay 
To assess the influence of the hypoxic environment to human HPs and SkMPs, we cultured cells 
under 2.5% O2 conditions in vitro as formerly described [52]. Concisely, HPs were seeded in 6-
well culture plates and allowed the cells to reach 80-90% confluence under the ambient oxygen 
concentration (21% O2). Upon the transition to low O2 conditions, the complete culture medium 
was removed and cells were washed twice with PBS before defined, serum-free DMEM medium 
was added. Twenty-four hours later, the culture supernatant and cell lysates were collected for 
analysis. Cells cultured under 21% O2 with the serum-free medium served as controls. 
4.2.9 RT-PCR 
Total RNA was extracted from 10
4
 cells using the Absolutely RNA nanoprep kit (Stratagene). 
cDNA was synthesized with SuperScript
TM
 II reverse transcriptase (Invitrogen). PCR was 
performed for 30 cycles at 58°C annealing temperature with Taq polymerase (Invitrogen), and 
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PCR products were electrophoresed on 1% agarose gels. Each set of oligonucleotides was 
designed to span two different exons so that genomic DNA contamination is of no concern.  
4.2.10 Matrigel culture/co-culture in vitro 
Cell culture and co-culture experiments using 2D and 3D Matrigel systems were performed, and 
capillary-like network formation was observed. In brief, 350µl of Matrigel (Becton-Dickinson) 
was placed in each well of a 24-well plate and incubated at 37°C for 30 min. Fifty thousand HPs 
were trypsinized, washed, and re-suspended in 700µl of EGM2
TM
 and subsequently seeded onto 
Matrigel-coated well. Experiments using 5x10
4
 HUVECs and 5x10
4
 SkMPs were performed as 
controls. A 2D co-culture system using cells pre-labeled with cell membrane dye (PKH26 red 
and PKH67 green fluorescent dye, Sigma-Aldrich) was used to observe HP-HUVEC interactions. 
Briefly, 5x10
4
 PKH26-labeled HUVECs (red) and 5x10
4 
PKH67-labeled HPs (Green) were well 
mixed, re-suspended in 700µl of EGM2
TM
, seeded onto Matrigel in a 24-well plate, and further 
cultured for 24 hours. An in vitro 3D Matrigel culture/co-culture system was developed to 
investigate vascular support by HPs. In short, 25x10
4
 PKH67-labeled HPs (green) were re-
suspended in EGM2
TM
 and well mixed with 350µl of Matrigel in a 3:1 ratio before being 
encapsulated into one well of a 24-well plate and subsequently incubated for 72 hours. Small 
amount of EGM2
TM
 was added after gelation and exchanged every 24-48 hours. Experiments 
using 25x10
4
 PKH26-labeled were performed as controls. A 3D co-culture system using 25x10
4
 
PKH26-labeled HUVECs (red) and 25x10
4 
PKH67-labeled HPs (green) was performed in the 
same manner and subsequently cultured for 72 hours. Another set of Matrigel co-culture plug 
was simultaneously exposed to hypoxic environment (2.5% O2) for 72 hours. The same 
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experiments using PKH67-labeled SkMPs (green) were performed for comparison. All images 
were taken using an epi-fluorescence microscope (Nikon Eclipse TE 2000-U). 
4.2.11 Statistical analysis 
All measured data are presented as mean ± standard deviation (SD). Statistical differences were 
analyzed by Student’s t-test (two groups) or one-way ANOVA (multiple groups) with 95% 
confidence interval. The Student-Newman-Keuls multiple comparison test was performed for 
post-hoc analysis of one-way ANOVA. Statistical analyses were performed with SigmaStat 
statistics software. 
4.3 RESULTS 
4.3.1 Identification of resident human microvascular pericytes within the ventricular 
myocardium 
To investigate whether microvascular pericytes residing in human ventricular myocardium 
express the previously defined combination of pericyte markers, we used immunohistochemistry 
to examine two adult and five fetal human ventricular biopsies. We observed consistent 
expression of known pericyte markers by human myocardial perivascular cells surrounding 
microvessels (diameter between 10-100μm) and capillaries (diameter less than 10μm), including 
NG2 (Figure 14A) and CD146 (Figure 14A-B and D-F), α-smooth muscle actin (αSMA) (Figure 
14B), smooth muscle myosin heavy chain (SM-MHC) (Figure 14B), and PDGFRβ (Figure 14C).  
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Figure 14: Identification of resident microvascular pericytes within human myocardium 
Perivascular cells residing in the microvessels of various sizes are identified by (A) co-expression of CD146 (green) 
and NG2 (red) (main and inset both X600) and (B) co-expression of CD146 (red) and α-SMA (main, green) or SM-
MHC (inset, green) (main and inset both X600). (C) Pericytes (white arrows) stained positive for PDGFR-β (red) 
surround vWF-positive endothelial cells (green) (X900). (D) Microvascular endothelial cells marked by CD34 
expression (green) are enclosed by CD146-positive perivascular cells (red) (X600). (E) A longitudinal section of the 
ventricular myocardium shows that endothelial cells marked by vWF (green) are surrounded by perivascular cells 
detected with an antibody against CD146 (red) (X200). (F) Transverse sections of microvessels display that CD146-
positive pericytes (green) surround CD144(+) (main, red, X600) and CD31(+) (inset, red, X900) endothelial cells. 
(scale bars = 100 m at X200, 50 m at X600, and 20 m at X900) 
Co-expression of NG2 and CD146 (Figure 14A main and inset), CD146 and αSMA 
(Figure 14B main) as well as CD146 and SM-MHC (Figure 14B inset) by myocardial 
perivascular cells was detected at microvessels of different sizes. PDGFRβ was also detected in 
all perivascular cells (Figure 14C, white arrows). Consistent with our previous reports, 
endothelial cell (EC) markers, including CD34 (Figure 14D), von Willebrand factor (vWF) 
(Figure 14C and E), CD144 (VE-cadherin) (Figure 14F main), and CD31 (Figure 14F inset), 
were not expressed by myocardial perivascular cells. Similar to microvascular pericytes in other 
tissues, expression of αSMA and SM-MHC were only noted in cells surrounding arterioles and 
venules but not around capillaries. Moreover, myocardial perivascular cells did not express 
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CD117 (c-kit) (Figure 15A-C, purple arrows) while approximately one third of CD117+ cells 
within the ventricular myocardium were located juxtapose to CD146+ pericytes and/or vWF+ 
ECs in microvessels/capillaries (Figure 15A-D, red arrows). These results indicate native cardiac 
heart pericytes display the same exclusive pericyte/perivascular cell surface phenotype as those 
found in other human organs.  
 
Figure 15: Human heart pericytes do not express c-kit in situ 
We did not observe native co-expression of c-kit and CD146 in resident heart pericytes in all samples examined 
(N=5 hearts) (A-D). Nevertheless, a fraction of c-kit+ cells (red arrows) reside anatomically adjacent to 
capillaries/microvessels, juxtapose to CD146+ pericytes (A-C, purple arrows) and/or vWF+ endothelial cells (D, 
green arrows). (All pictures are taken at X400, scale bars=50m) 
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4.3.2 Purification and culture of human heart pericytes 
To prospectively purify human HPs using multi-color fluorescence-activated cell sorting (FACS), 
two adult and 12 fetal (17 to 23 weeks) heart biopsies were independently processed. Briefly, 
epicardium and endocardium were microscopically removed from all biopsies, and only 
ventricular myocardium was harvested for cell isolation, followed by mechanical dissociation 
and collagenase digestion. Before being subjected to fluorescence-activated cell sorting (FACS) 
for purification, cells were stained with fluorescence-conjugated antibodies to a panel of 
selective cell lineage markers, including CD34 (progenitor/endothelial cells), CD45 
(leukocytes/hematopoietic cells), CD56 (neural/myogenic/NK cells), CD117 
(hematopoietic/cardiac precursor cells), and CD146 (pericyte/endothelial cells). To be devoid of 
contamination from circulating hematopoietic and/or resident cardiac precursor cells, CD117+ 
cells were initially gated out of myocardial cell suspensions, followed by the exclusion of 
CD45+ and CD56+ cells as described in our previously published protocols (Figure 16A). Heart 
pericytes (HPs) were subsequently identified and gated by robust CD146 expression with the 
absence of CD34, the latter used to ensure the avoidance of EC contamination (Figure 16A). HPs 
(CD146
+
CD34
-
CD45
-
CD56
-
CD117
-
) were sorted to homogeny at a frequency of 1.21 ± 0.52%, 
similar to the reported ratio of pericytes (CD146
+
CD34
-
CD45
-
CD56
-
)
 
present in other organs.  
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Figure 16: Purification and culture of ventricular microvascular pericytes 
(A) FACS sorting of ventricular microvascular pericytes: CD117(-) fraction was first separated, followed by the 
selection of CD45(-)CD56(-) fraction, and finally separated by CD34(-)CD146(+) selection of heart pericytes (HPs). 
(B) The morphology of cultured heart pericytes (HPs, left panel) was very similar to that of skeletal muscle pericytes 
(SkMPs, right panel) (X100, Scale bars = 200 m). (C) RT-PCR analysis confirmed that sorted HPs express pericyte 
markers: CD146, αSMA, and NG2 but not endothelial cell markers: CD34, CD31, CD144, and vWF. (D) Cultured 
HPs express typical pericyte markers, including ALP, NG2, αSMA as well as PDGFRα, revealed by 
immunocytochemistry. 
 Sorted HPs were cultured in typical pericyte medium, commonly exhibiting an 
elongated, rectangular morphology with extended arms, similar to their skeletal muscle 
counterparts at sub-confluence (Figure 16B). RT-PCR confirmed the homogeneity of freshly 
sorted HPs (Figure 16C). Purified HPs can be cultured over the long term and maintain the 
expression of selection marker profile (Figure 17A). The cell growth of HPs in long-term culture 
is comparable with skeletal muscle-derived pericytes: a population doubling time (PDT) of 
approximately 60 hours at passage 3-12, no apparent contact inhibition at confluence, occasional 
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formation of spherical structures at early passages (Figure 17B), and maximal population 
doublings of forty or more, except a seemingly shorter initial growth retardation (first 4 weeks 
after sorting). Immunocytochemistry revealed that cultured HPs express common pericyte 
markers such as alkaline phosphatase (ALP), NG2, αSMA as well as PDGFRα (Figure 16D). 
Further analyses using flow cytometry demonstrated expression of classic MSC markers by 
cultured HPs, including CD44, CD73, CD90, and CD105, similar to pericytes of other origins 
(Figure 17C).   
 
Figure 17: Heart pericytes stably express FACS-selection and MSC marker profile in long-term culture 
(A) Purified heart pericytes were maintained in culture for 9 weeks and analysed by flow cytometry for FACS-
selection marker expression. Cells were detached with trypsin and stained with fluorescence-conjugated antibodies: 
CD34-APC, CD45-APC-Cy7, CD56-PE-Cy7, and CD146-FITC. Analyses were performed with the same gating 
used to sort heart pericytes. (B) Representative pictures showing that cultured HPs from two donors, designated 
HP#1 (a) and #2 (b), occasionally form spherical structures at early passages with no obvious contact inhibition at 
confluence (scale bars: (a)=200m, (b)=100m) (C) Long-term cultured heart pericytes were also analysed for 
expression of pericyte/stem cell marker, CD146 and alkaline phosphatase (ALP), as well as classic MSC markers, 
including CD44, CD73, CD90, CD105. 
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4.3.3 Heart pericytes support microvascular structures yet exhibit distinctive behaviors in 
response to hypoxia 
 
Figure 18: Heart pericytes form capillary-like networks in 2D and 3D Matrigel culture 
(A) Human heart pericytes seeded onto Matrigel-coated wells formed typical capillary-like networks within 6-12 
hours. (B) Dye-labeled pericytes (green) and HUVECs (red) co-formed capillary-like networks within 6-12 hours. 
(C) Enlargement of the dotted area in (B) showed that HUVECs (Red) appear to line and spread out on top of the 
pericyte-formed structures (Green). (D-F) To simulate native capillary formation, heart pericytes were evenly 
encapsulated into 3D Matrigel plug for up to 180 hours. Pericytes formed 3D networks with structural organization 
and maturation over time. (G-I) HUVECs were encapsulated into 3D Matrigel plug in the same manner but unable 
to form any organized structure. (All pictures are taken at X100, scale bars = 200 m, except (C) taken at X200, 
scale bars = 100 m) 
To demonstrate that HPs support the integrity of microvascular structures, we used 2D and 3D 
Matrigel culture/co-culture systems. HPs alone seeded onto Matrigel-coated wells formed 
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capillary-like networks within 6-12 hours (Figure 18A), resembling those formed by HUVECs in 
24 hours (not shown). Dye-labeled HPs (green) and HUVECs (red) co-formed capillary-like 
networks within 6-12 hours (Figure 18B), with HUVECs appearing to line and spread out on top 
of HP-formed structures (Figure 18C). To mimic native capillary formation, 3D Matrigel plugs 
encapsulating evenly distributed HPs or HUVECs were cultured. Dye-labeled HPs formed 3D 
capillary-like networks with structural maturation and remodeling over time (Figure 18D-F) 
while HUVECs did not form any organized structure in the same condition (Figure 18G-I).  
 
Figure 19: Vascular support function of human heart pericytes under hypoxia 
When dye-labeled heart pericytes (Green) and HUVECs (Red) were evenly casted into the 3D Matrigel plug, (a-c) 
these two types of cells migrated and co-formed microvessel-like networks together within 72 hours under the 
ambient oxygen concentration (21% O2), with pericytes assuming peri-HUVEC positions. (d-f) When the Matrigel 
plug was exposed to hypoxic conditions (2.5% O2), the co-formation of microvessel-like networks was facilitated. 
(All pictures are taken at X100, scale bars=200m) 
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The same 3D Matrigel plug culture was applied to study the interaction between HPs and 
HUVECs under the ambient (21%) or low (2.5%) oxygen concentration, in comparison with 
SkMPs isolated from the same donor. HPs (green) and HUVECs (red) gradually formed 3D 
capillary-like networks together within the plug in 72 hours under 21% O2 (Figure 19A, a-c). 
Notably, such a process appeared to be facilitated under 2.5% O2 (Figure 19A, d-f). Altogether 
these data suggest that cultured HPs not only retained mural cell features, supporting formation 
of microvascular networks, but also exhibiting angiogenic behaviors divergent from SkMPs 
under low oxygen tension. 
4.3.4 Cardiomyogenic potential of human heart pericytes  
To investigate the cardiomyogenic potential of HPs, we first used DNA demethylation method 
for induction in vitro, according to published protocols. Cultured HPs were incubated with 
induction medium containing 10µM 5-azacytidine for 72 hours and then back in regular medium 
for additional 14 days. Immunocytochemistry most HPs expressed (a) GATA4, and a fraction of 
them express (b) α-actinin and (c) cardiac myosin heavy chain (Figure 20, a-c). 
 
Figure 20: Cardiomyocyte differentiation of human heart pericytes 
After incubation in cardiomyogenic induction medium containing 10µM 5-azacytidine for 72 hours and then in 
pericyte medium for additional 14 days, most HPs expressed (a) GATA4, and a fraction of them express (b) α-
actinin and (c) cardiac myosin heavy chain (scale bars=100m). 
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4.3.5 Heart pericytes natively express MSC markers 
As we and others have previously shown that microvascular pericytes in many tissues manifest 
typical MSC markers in situ, we investigated if HPs shared this phenotype in the myocardium. 
Immunohistochemistry revealed that HPs surrounding ECs of small blood vessels in the 
ventricular myocardium natively express classic MSC markers, including CD44 (Figure 21A), 
CD73 (Figure 21B), CD90 (Figure 21C, main and inset), and CD105 (Figure 21D). Particularly, 
only microvascular pericytes expressed CD105 (Figure 21D enlargement, red arrows) but not 
perivascular cells surrounding the larger blood vessel (Figure 21D, dotted encirclement). 
Confocal microscopy confirmed the co-expression of CD146 and CD44 (Figure 21E) or CD90 
(Figure 21F) by HPs. Flow cytometry was further employed to validate that freshly purified HPs 
retain the expression of MSC markers. The results showed that HPs (CD146
+
CD34
-
CD45
-
CD56
-
CD117
-
) (Figure 21G, a) co-express ALP, CD44, CD73, CD90, and CD105, but not CD133 
(Figure 21G, b-g).  
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Figure 21: Heart pericytes natively express MSC markers 
Left column: frozen sections of human myocardial tissue were co-stained with antibodies to classic MSC markers, 
including CD44 (A, red), CD73 (B, green), CD90 ([C] main, red; [C] inset, green), and CD105 (D, red) as well as 
endothelial cell markers: vWF (A and D, green), the Ulex europaeus lectin receptor (UEA-1R) (B and [C] inset, red), 
or CD34 ([C] main, green). Pericytes surrounding small blood vessels express CD44 (A, X900), CD73 (B, X900), 
CD90 ([C] main, X900), and CD105 (D, X400) (scale bars: A-[C] main=20m; D=50m). Pericytes encircling 
UEA-1R+ capillaries also strongly express CD90 ([C] inset, X900, scale bars=10m). Notably, CD105 is only 
expressed by microvascular pericytes ([D] enlargement, red arrows) but not by perivascular cells surrounding the 
larger vWF+ vessel (D, dotted encirclement). Middle column: frozen sections of human myocardial tissue were 
triple-labeled with antibodies to vWF (green), CD146 (white), and either CD44 (E, red) or CD90 (F, red). Confocal 
microscopy revealed that pericytes encircling capillaries and microvessels express both CD44 (E, X1000) and CD90 
(F, X1000) in addition to CD146 (white/red arrows) (scale bars=10m). Right column: (G) HPs freshly isolated 
from human myocardium were incubated with antibodies to stem cell and MSC markers and analyzed by flow 
cytometry. CD146
high
CD34
-
CD45
-
CD56
-
CD117
-
 population were first gated (a) and examined for co-expression of 
ALP (b), CD133 (c), CD44 (d), CD73 (e), CD90 (f), and CD105 (g). Clear histograms (b-g) represent negative 
control cells stained with non-specific isotype-matched antibodies.  
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4.3.6 Heart pericytes exhibit mesodermal differentiation capacity except skeletal 
myogenesis 
After demonstrating that HPs manifest MSC markers natively and in culture, we then 
investigated whether HPs possess multi-lineage mesodermal differentiation potential resembling 
pericytes originated from other organs. Cultured HPs were incubated in inductive conditions for 
osteo-, chondro-, adipo-, and myo-genesis respectively. Compared with SkMPs exhibiting all 
four mesodermal lineage differentiations (Figure 22B, e), HPs displayed robust osteo-,  chondro-, 
and adipo-genic differentiation, but not myotube formation, even after extended incubation for 
up to 3 weeks (Figure 22A, a-c and Figure 22B, d). We further examined the difference between 
HPs and SkMPs in skeletal myogenesis in vitro. Differentiated SkMPs expressed mature muscle 
proteins, including fast skeletal myosin heavy chain (FS-MHC), slow skeletal myosin heavy 
chain (SS-MHC), and desmin, while HPs did not display any of the three markers after culturing 
in muscle fusion medium for 7 days (Figure 22C). To investigate whether this tissue-specific 
difference in myogenesis sustains in vivo, HPs and SkMPs were isolated from the same donor, 
and fifty thousand cultured cells injected into cardiotoxin-injured skeletal muscles of 
immunodeficient mice. Immunohistochemistry with human-specific spectrin antibody showed 
that only SkMPs regenerated human myofibers (N=4), no human spectrin-positive myofiber was 
detected in HP-injected muscles (N=4) (Figure 22D). 
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Figure 22: Heart pericytes exhibit mesodermal differentiation except skeletal myogenesis 
(A) Cultured HPs were examined for mesodermal differentiation capacity in inductive conditions for osteo-, 
chondro-, adipo-, and myo-genesis respectively. Compared with SkMPs, which previously reported to exhibit all 
four mesodermal lineage differentiations after incubation, HPs displayed robust (a) osteo-, (b) chondro-, and (c) 
adipo-genic differentiation, revealed by alizarin red, Alcian blue, Oil red O stainings respectively. (B) But unlike 
SkMPs (e), HPs did not manifest myotube formation (d) even after extended incubation for up to 3 weeks. (C) 
Skeletal myogenesis in vitro was further evaluated by immunocytochemistry. Mature myogenic markers, including 
fast skeletal myosin heavy chain (FS-MHC) and slow skeletal myosin heavy chain (SS-MHC), as well as early 
myogenic marker, desmin, were expressed by SkMPs, but not by HPs, after culturing in muscle fusion medium for 7 
days (scale bars=200 m). (D) To investigate whether this tissue-specific difference in myogenesis sustains in vivo, 
fifty thousand cultured HPs or SkMPs, isolated from the same donor, were injected into cardiotoxin-injured 
gastrocnemius muscles of SCID-NOD mice. Two weeks later, frozen sections of recipient muscles were stained with 
human-specific spectrin antibody to reveal newly regenerated myofibers of human origin. In contrast to the large 
number of human myofibers regenerated by SkMPs in all samples (N=4), no human spectrin-positive myofiber was 
identified in HP-injected muscles (N=4) (scale bars=100 m).  
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4.4 DISCUSSION 
Recently, preliminary reports from clinical trials (SCIPIO and CADUCEUS) using resident 
cardiac progenitor/precursor cells (CPCs) have demonstrated encouraging results, indicating the 
safety of using autologous CPCs for post-infarction repair/regeneration [139, 140]. Although 
recent progresses in mammalian cardiac developmental and stem cell biology have greatly 
advanced our understanding of resident heart stem/progenitor cells, the perivascular 
compartment within the heart has not yet been fully studied [18, 141]. The importance of 
perivascular precursor cells contributing to physiological functions and participating in 
pathological conditions has recently been demonstrated by several groups [9, 53, 142, 143].  
Despite prior studies by our and other groups have extensively characterized 
microvascular pericytes isolated from multiple human organs, it is not clear whether pericytes 
residing in the heart possess multi-lineage differentiation capacity and/or stem cell characteristics 
[17, 26, 113]. More importantly, despite their seemingly universal mesodermal multipotency as 
well as stem/progenitor cell features, whether tissue specificity and/or divergent behaviors to 
pathophysiological conditions exist among pericytes of different organs, notably of distinct 
developmental origins, remains unknown [138].  
In the current study, we described that resident HPs express known pericyte markers and 
can be prospectively purified HPs to homogeny with a combination of cell lineage antigens. HPs 
natively express no CD117 and thus differ from CD117+ cardiac precursor cells. Sorted HPs 
(CD146
+
CD34
-
CD45
-
CD56
-
CD117
-
) can be cultured long term and exhibit nearly identical 
phenotypes as their counterparts in other organs. HPs support formation of capillary-like network 
in 2D and 3D Matrigel culture, with or without endothelial cells, and further facilitate this 
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angiogenic process under low oxygen conditions, which is presumably attributed to the increased 
secretion of angiogenic factors and accelerated migration by HPs in response to decreased 
concentration. Coupled with their paracrine function, HPs may hold great advantage to treat 
ischemic heart diseases. Given the rarity and indispensability of cardiac tissue, however, future 
applications of HPs as a therapeutic cell source may be limited to critical conditions. Yet the 
therapeutic potency of HPs in cardiovascular repair and regeneration demands further 
investigation.  
Coronary vasculature, including microvessels and capillaries, has previously been shown 
to arise from an epicardial origin, which differs from vasculature of other tissues, for example, 
skeletal muscle. Recent evidence from a transgenic murine model indicated that multipotent 
mesenchymal precursors residing in the heart originate from proepicardium (recent CSC paper). 
These data suggest that resident HPs presumably arise from proepicardium/epicardium along 
with coronary vasculature tree and contribute to this mesenchymal precursor pool. Whether HPs 
actively participate in congenital or acquired pathological conditions of the heart awaits further 
research. 
Despite certain histological similarity as striated muscle, myocardium and skeletal muscle 
differ greatly in their developmental origin and physiological function. By comparing HPs with 
SkMPs, we observed a tissue-specific restriction of skeletal myogenic differentiation in HPs as 
well as their differential responses to oxygen concentrations. Nevertheless, HPs not only express 
MSC marker in situ and in culture but also demonstrated robust mesenchymal differentiations 
such as osteo-, chondro-, and adipo-genesis, comparable to pericytes from other tissues. More 
effort is required to elucidate if there are additional types of tissue specificity existing among this 
seemingly universal population of vascular mural cells throughout the body. 
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4.5 CONCLUSION 
In summary, herein I demonstrate that resident HPs can be identified by typical pericyte markers 
and purified by a modified panel of selective markers. Purified HPs are multipotent 
mesenchymal precursors residing in human myocardium, exhibiting tissue specificity in 
differentiation capacity and distinct angiogenic responses to low oxygen tension. Although HPs 
do not express c-kit, their developmental hierarchy and relationship to other resident cardiac 
precursor cells remain to be elucidated. Additionally, it is worth mentioning that it has been 
extremely difficult to obtain healthy adult human myocardial biopsies in Pittsburgh area. The UK 
team, however, was able to obtain several and perform histological analyses and cell isolation.  
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5.0  PATH TO CLINICAL TRANSLATION: COMPARISON OF SKELETAL 
MYOGENESIS BETWEEN LINEAGES AND EXPLORATION OF ALTERNATIVE 
SOURCE OF BLOOD-VESSEL-DERIVED STEM CELLS  
5.1 INTRODUCTION 
As described in previous chapters, blood-vessel-derived stem cells (BVSCs) are composed of a 
number of stem cells originated from different vascular cell lineages, including myogenic 
endothelial cells (MECs) of endothelial cell lineage as well as pericytes and adventitial cells 
(ACs) of perivascular cell lineage. It is not yet clear whether all BVSC populations possess the 
same regenerative capacity in pathological conditions, for instance skeletal muscle injury, and 
how this difference of lineage origin could affect their capacity in tissue repair/regeneration. To 
identify optimal BVSC cell type(s) for particular organ injury/disease applications, it is deemed 
critical to understand the relative capacity of different BVSC populations to repair/regenerate 
tissue under a specific pathological condition. MECs and pericytes have only been shown to be 
superior to myoblasts for muscle regeneration in separate studies. Herein I used skeletal 
myogenesis as a model system to directly compare the efficiency of muscle repair between 
MECs and pericytes isolated from the same donor. Moreover, to further facilitate clinical 
translation of BVSCs, it is essential to investigate whether we can isolate BVSCs from any 
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alternative source, more convenient and clinically accessible than fresh tissue biopsies in terms 
of preservation and processing time.  
Mammalian skeletal muscle harbors all three BVSC populations, which can repair and/or 
regenerate injured/defective tissues such as damaged/dystrophic skeletal muscles and ischemic 
hearts [1, 46, 83, 144-152]. These stem cell populations were specifically localized in situ within 
the walls of small blood vessels as described above and can be prospectively purified by 
fluorescence-activated cell sorting (FACS) simultaneously from fresh human skeletal muscle 
biopsies, through the use of a combination of positive and negative cell lineage markers [26, 45]. 
However, it has never been documented whether these stem cell fractions could persist and retain 
their high myogenic capacities after the cryopreservation of human primary skeletal muscle cell 
cultures (cryo-hPSMCs). Furthermore, whether MECs isolated from cryopreserved, culture-
expanded hPSMCs also possessed the same superior regenerative capacity remains to be 
determined. 
 In order to identify and purify MECs and pericytes by FACS from in vitro expanded 
cryo-hPSMCs, we employed a collection of cell lineage markers reported in our previous studies, 
including the hematopoietic cell marker CD45, the myogenic cell marker CD56 (N-CAM), the 
perivascular cell marker CD146 (M-CAM/Mel-CAM/MUC18), and the endothelial cell marker 
UEA-1 receptor (Ulex europaeus agglutinin I receptor, UEA-1R) [26, 45, 153]. UEA-1R was 
chosen as a substitute marker for CD34 and CD144 because these two endothelial cell markers 
are frequently lost during long-term culture whereas UEA-1 maintains consistent reactivity 
within endothelial cell lineage cultures [45, 153]. We hypothesized that MECs and pericytes 
(with and without culture expansion), purified from cryo-hPSMCs, retain their superior 
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myogenic potential and exhibit greater regeneration of skeletal myofibers when compared to 
myoblasts.  
5.2 MATERIALS AND METHODS 
5.2.1 Human muscle biopsies and animal usage 
In total, nine independent human skeletal muscle biopsies, from 4 female and 5 male donors (age 
range 4–75, mean 28), were used to obtain human primary skeletal muscle cells (hPSMCs). The 
procurement of human skeletal muscle biopsies from the National Disease Research Interchange 
(NDRI) was approved by the Institutional Review Board at the University of Pittsburgh Medical 
Center (UPMC). All the animal research experiments performed in this study were approved by 
the Animal Research and Care Committee at the Children’s Hospital of Pittsburgh of UPMC 
(Protocol #34-05) and the University of Pittsburgh (Protocol #0810310-B2). 
5.2.2 Cell isolation and cryopreservation 
The human skeletal muscle biopsies were placed in Hank’s balanced salt solution (HBSS, 
Invitrogen) and transferred to the laboratory on ice. Briefly, tissues were finely minced and 
serially digested with 0.2% collagenase-type XI, 0.25% dispase, and 0.1% trypsin, as previously 
described [45, 153]. Dispersed single cell suspensions were either labeled freshly for cell sorting 
or cultured in complete medium containing DMEM supplemented with 10% fetal bovine serum 
(FBS), 10% horse serum, 1% chicken embryo extract, and 1% penicillin/streptomycin (all from 
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Invitrogen). After expansion, cells were cryopreserved at passages 2-8 in medium consisting of 
50% complete culture medium and 50% freezing medium (80% FBS+20% dimethylsulfoxide) 
and stored in liquid nitrogen [153].  
5.2.3 Flow cytometry and cell sorting 
FACS sorting of freshly isolated muscle cells were described in Chapter 3. To culture cryo-
hPSMCs, cells were thawed and expanded for 2-6 passages. To perform flow cytometry analysis, 
cells were trypsinized, washed, and incubated with anti-human monoclonal antibodies/ligands: 
CD45-APC-Cy7, CD56-PE-Cy7, CD34-APC (all from Becton Dickinson), CD146-FITC 
(Serotec), UEA-1-PE (Biomeda), vWF-FITC (US Biology), KDR-APC (R&D System) and 
CD144-PE (Beckman Coulter). Negative control samples received equivalent amounts of 
isotype-matched fluorophore-conjugated antibodies. For FACS purification, cells were incubated 
with CD45-APC-Cy7, CD56-PE-Cy7, CD146-FITC, UEA-1-PE, and with 7-amino-actinomycin 
D for dead cell exclusion. Sorted subpopulations were collected for immediate transplantation or 
transiently expanded in appropriate conditions as previously described [26, 45].  
5.2.4 Immunocytochemistry 
For immunocytochemistry, cells were either directly fixed in wells with cold methanol for 5 min 
or cytospun onto glass slides, fixed, and incubated with 10% serum. The following primary 
antibodies were used to detect cell lineage markers, including myogenic cell markers, CD56 
(Becton-Dickinson, 1:100), fast skeletal myosin heavy chain (FS-MHC, 1:200), slow skeletal 
myosin heavy chain (SS-MHC, 1:200) and desmin (1:100) (all from Sigma); perivascular cell 
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markers, α-smooth muscle actin (Abcam, 1:100) and CD146 (Cayman Chemical, 1:50); 
endothelial cell markers/ligands, CD144 (Sigma, 1:100), von Willebrand factor (vWF, 1:100) 
(DAKO), CD34 (Novocastra, 1:50), and biotinylated UEA-1 (Vector, 1:50), followed by 
incubation with biotinylated secondary antibodies plus Cy3-conjugated streptavidin (both from 
Sigma, 1:500) or Alexa
TM
488-conjugated secondary antibodies (Molecular Probes, 1:400). Plates 
and slides were observed and photographed on epi-fluorescence microscope systems (Nikon 
Eclipse TE 2000U and Nikon Eclipse E800).  
5.2.5 Myogenesis in vitro and in vivo 
5.2.5.1 Myogenesis in vitro 
Myogenesis in vitro has been described in Chapter 4. MECs and pericytes isolated from the same 
fresh muscle biopsy along with HUVECs, which represent typical endothelial cells (ECs), were 
cultured under the same myogenic condition.  
5.2.5.2 Myogenesis in vivo 
To investigate whether the myogenic capacities were preserved, after cryopreservation, purified 
MECs, pericytes, myoblasts (Myo), ECs and unpurified muscle cells, without in vitro expansion, 
from six independent hPSMC samples were used for intramuscular injection. The newly sorted 
cells, on average, 11.8±5.8×10
4
 CD56
+
 Myo, 7.3±4.4×10
4 
CD146
+
 pericytes, 4.5±2.6×10
4
 UEA-
1R
+
 ECs, and 2.9±1.7×10
4 
CD56
+
UEA-1R
+
CD146
+
 MECs as well as 30×10
4 
corresponding 
unsorted cells, were resuspended in 20µl of HBSS and used for transplantation.  
To precisely measure the myogenic regenerative capacity of each stem/progenitor cell 
subpopulation, newly sorted MECs, pericytes and Myo were expanded in culture for 1-2 
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passages. Fifty-thousand cells from each subpopulation as well as 5×10
4 
corresponding unsorted 
cells were trypsinized, washed and resuspended in 20µl of phosphate-buffered saline (PBS). 
Four individual animal experiments were performed, with each using cell populations purified 
from a single FACS sort of one independent cryo-hPSMC culture. 
Cells were injected into a single site of the gastrocnemius muscles of severe combined 
immunodeficient (SCID) mice that were injured 24 hours before by injecting 1µg of cardiotoxin 
in 20µl of HBSS. The untreated group received sham injections of 20µl of HBSS or PBS only. 
Treated muscles were collected 2 weeks post-injection for immunohistochemical analyses. Anti-
human spectrin was used to identify human cell-derived skeletal myofibers in the mouse muscles. 
In order to quantitatively evaluate the myogenic regenerative capacity of each subpopulation, the 
number of human spectrin-positive skeletal myofibers was averaged from 6 randomly selected 
sections at the site of the injection in each specimen and presented as the regenerative index (per 
section). 
5.2.6 Statistical analysis 
Data were summarized as average ± standard error (SE). Statistical comparison between groups 
(purified cells after expansion in vitro) was performed using one-way ANOVA with 95% 
confidence interval. Bonferroni pairwise multiple comparison test was performed for ANOVA 
post-hoc analysis. Statistical analyses were performed with SigmaStat software. 
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5.3 RESULTS 
5.3.1 Myogenic endothelial cells exhibited the supreme myogenic capacity in culture  
MECs and pericytes were simultaneously purified from a single human skeletal muscle biopsy 
by FACS, with a post-sort purity greater than 95 percent. Cells were expanded in culture 
according to previously reported conditions until confluence (Figure 23A-C). When cultured in 
the same myogenic condition, MECs exhibited the greatest extent of myotube formation (Figure 
23F) when compared to other cell populations. Pericytes formed less and smaller myotubes 
(Figure 23E) while nearly all HUVECs did not survive the typical myogenic culture (Figure 
23D).  
 
Figure 23: Myogenesis of BVSC populations in vitro 
(A-C) Before switching to myogenic culture condition (2% serum), cells were expanded until confluence. After 1 
week of myogenic differentiation, MECs displayed the highest extent of myotube formation (F) while pericytes 
formed less and smaller myotubes (E). However, nearly all HUVECs did not survive in the typical myogenic culture 
condition (D).  
Further analyses of myogenic markers revealed that after differentiation, MECs 
extensively displayed mature myogenic markers, FS-MHC and SS-MHC (Figure 24G-H), while 
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nearly all of the MECs express early myogenic marker, desmin (Figure 24I). On the other hand, a 
notably smaller proportion of pericytes express FS-MHC, SS-MHC, and desmin (Figure 24D-F), 
indicating a smaller extent and lesser maturation of myogenesis than those of MECs. Near 
extinction of HUVECs in myogenic culture was confirmed by DAPI staining with no apparent 
myogenic marker expression (Figure 24A-C) 
 
Figure 24: Immunocytochemical analyses of myogenic markers 
(A-C) After myogenic differentiation for 7 days, near extinction of HUVECs in myogenic culture was confirmed by 
DAPI staining with no apparent myogenic marker expression. A fraction of pericytes expressed mature myogenic 
markers, FS-MHC (D) and SS-MHC (E), as well as early myogenic marker, desmin (F). A notably larger proportion 
of MECs displayed FS-MHC (G), SS-MHC (H), and desmin (I). 
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5.3.2 Heterogeneous cell composition of human primary skeletal muscle cell cultures 
(hPSMCs) after cryopreservation and long-term expansion 
After expansion, the cryopreserved hPSMCs (cryo-hPSMCs) were examined by 
immunocytochemistry for cell surface marker expression. The majority of cryo-hPSMCs 
expressed desmin and CD56, and to a lesser extent, CD146 (Figure 25A). Only a fraction of cells 
expressed α-SMA, CD144, vWF or UEA-1R. As predicted, the cultured human cryo-hPSMCs 
lacked CD34 expression. After excluding CD45
+
 hematopoietic cells (0.2±0.1%), flow 
cytometry analysis quantitatively confirmed the presence of cells with diverse expressions of cell 
lineage makers by cryo-hPSMCs: 77.1±5.7% CD56
+
, 66.9±8.1% CD146
+
, 11.2±2.5% UEA-1R
+
, 
0.3±0.1% CD144
+
, 0.1% vWF
+
, and null expression of CD34 and KDR (Figure 25B). The 
number of cryo-hPSMCs positive for CD56, CD146 or UEA-1R decreased dramatically after 
passage 10 (Figure 25C). 
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5.3.3 Isolation of myogenic stem/progenitor cells from cryo-hPSMCs 
 
Figure 25: Expression of cell lineage markers by cryo-hPSMCs 
(A) Immunocytochemistry revealed the expression of various cell lineage markers (red) by cryopreserved human 
primary skeletal muscle cells (cryo-hPSMCs) after expansion. Nuclei were stained blue with DAPI. (B) Flow 
cytometry analysis quantitatively confirmed the diverse cell composition of cryo-hPSMCs. (C) The number of cryo-
hPSMCs positive for CD56, CD146, or UEA-1R decreased when cells were cultured beyond passage 10. (Scale bars 
= 100µm) 
After revealing the heterogeneous nature of cryo-hPSMCs, we analyzed these cells for the 
existence of previously defined subpopulations by multi-color flow cytometry, based on their 
expression of hematopoietic (CD45), myogenic (CD56), endothelial (UEA-1R), and perivascular 
(CD146) cell lineage markers [26, 45]. After exclusion of CD45
+ 
cells, four distinct cell fractions 
were identified, including myoblasts (Myo) (CD56
+
/CD45
-
CD146
-
UEA-1R
-
), endothelial cells 
(ECs) (UEA-1R
+
/CD45
-
CD56
-
CD146
-
), pericytes (CD146
+
/CD45
-
CD56
-
UEA-1R
-
), and 
myogenic endothelial cells (MECs) which expressed all three markers (CD56
+
UEA-
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1R
+
CD146
+
/CD45
-
). Long-term cultured cryo-hPSMCs included 22.58±6.32% Myo, 0.58±0.23 
% ECs, 5.92±4.66% pericytes, and 1.16±0.19% MECs (Figure 26). These four cell subsets were 
subsequently fractionated by FACS, and on average we were able to recover the following 
number of each cell type: 25.61±9.16×10
4
 CD56
+
 Myo, 13.28±7.37×10
4
 UEA-1R
+
 ECs, 
33.54±20.53×10
4 
CD146
+
 pericytes, and 3.84±0.96×10
4 
CD56
+
UEA-1R
+
CD146
+
 MECs (Figure 
26). 
 
Figure 26: Identification and purification of myogenic stem cells within cryo-hPSMCs 
After excluding CD45
+
 hematopoietic cells, CD45
-
 cells were separated based on CD56 expression. CD56
+
 and 
CD56
-
 populations were further gated on UEA-1R by CD146 to identify and/or sort four distinct cell populations: 
myogenic endothelial cells (MEC) (CD56
+
UEA-1R
+
CD146
+
/CD45
-
), myoblasts (Myo) (CD56
+
/CD45
-
CD146
-
UEA-
1R
-
), pericytes (CD146
+
/CD45
-
CD56
-
UEA-1R
-
), and endothelial cells (EC) (UEA-1R
+
/CD45
-
CD56
-
CD146
-
). The 
purities of the sorted populations were 90.73±4.82%, 92.94±1.23%, 93.86±1.72, and 94.9±0.64, respectively. 
Immunocytochemistry confirmed the expression of key cell lineage makers by freshly sorted cells: UEA-1R, CD146, 
and/or CD56. Nuclei were stained blue with DAPI. (Scale bars = 100µm except in CD56/UEA-1R double staining = 
20µm) 
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5.3.4 Purified myogenic stem/progenitor cells retain high myogenic potentials in vivo   
 
Figure 27: Myogenic capacity of cryo-hPSMC culture-derived cells in vivo 
Representative pictures of regenerating human spectrin-positive myofibers in cardiotoxin-injured mouse skeletal 
muscles transplanted with newly sorted cell fractions from a single donor-derived cryo-hPSMC culture, including 
myogenic endothelial cells (MEC), pericytes, endothelial cells (EC), and myoblasts (Myo). Unsorted cryo-hPSMCs 
(Unsort) and HBSS were injected as treated and untreated controls respectively. (200X, scale bars = 50µm)  
To evaluate whether the myogenic capacity was preserved after cryopreservation, all sorted cells 
were immediately transplanted (without culture expansion) into the cardiotoxin-injured 
gastrocnemius muscles of SCID mice (n=6 per cell fraction). Unpurified muscle cells and Hank’s 
balanced salt solution (HBSS) injections were employed as treated and untreated controls, 
respectively. Mouse muscles were harvested 2 weeks post-injection, cryosectioned, and 
examined by immunohistochemistry to detect muscle fiber regeneration. An antibody against 
human spectrin, a myofiber cytoskeletal protein, was used to identify human cell-derived skeletal 
myofibers in the tissue sections. All of the newly purified cell fractions regenerated human 
spectrin-positive myofibers in injured mouse skeletal muscles, and the purified fractions appear 
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to be more efficient at regenerating muscle fibers than the unpurified cryo-hPSMCs (Figure 27). 
As expected, a lack of spectrin-expressing muscle fibers was observed in the HBSS-injected 
muscles (Figure 27).  
To quantitatively measure the myogenic regenerative capacity of each purified 
stem/progenitor cell population, newly sorted MECs, pericytes and Myo were transiently 
expanded in culture for 1-2 passages. Fifty-thousand cells from each subpopulation as well as 
5×10
4 
corresponding unsorted cells were transplanted into the same muscle-injury model (n=4 
per cell fraction). Phosphate-buffered saline (PBS) injections were used as negative controls. 
ECs were not included in this experiment due to their unstable phenotypes in culture. 
Quantitative analyses revealed that the myogenic regenerative index, indicated by the average 
number of human spectrin-positive skeletal myofibers per muscle section, was 166.3±19.2 for 
MECs, 90.1±8.0 for pericytes, 45.7±6.2 for myoblasts (Myo), and 28.7±8.4 for unsorted muscle 
cells (Unsort) (Figure 28). MECs exhibited the highest regeneration of human skeletal myofibers 
among all four cell fractions tested (p<0.005) (Figure 28). Pericytes regenerated more myofibers 
than the Myo (p>0.05) and the Unsort (p=0.017) (Figure 28). Although the purified myoblasts 
displayed a trend of higher myogenic capacity than the unsorted cells, no statistically significant 
difference was observed (p>0.05) (Figure 28). 
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Figure 28: Comparison of myogenic regeneration in vivo 
Quantitative analyses of the myogenic regenerative capacities of sorted stem/progenitor cell populations. Fifty-
thousand cells from each cell fraction that was minimally expanded in culture were injected. Quantitative analyses 
of spectrin-positive human skeletal myofibers on tissue sections revealed that MEC mediated the highest myogenic 
regeneration among all four cell fractions tested (*p<0.001, vs. Myo and Unsort; †p=0.004, vs. pericytes). Injection 
of pericytes regenerated more human myofibers than injections of Myo (p>0.05) and Unsort (#p=0.017). Finally, 
Myo displayed a trend of higher myogenic capacity than Unsort, but no significant difference was observed (p>0.05). 
5.4 DISCUSSION 
Skeletal muscle is known to possess multiple stem/progenitor cell populations that are associated 
with muscle development, maintenance, and regeneration [1, 154]. Upon purification, muscle 
stem/progenitor cells in general display more robust myogenic regenerative capacities than 
unpurified muscle cells in animal disease models, suggesting the advantage of isolating stem 
cells for therapeutic purposes [1, 26, 45, 144]. More recent data has shown that there is a 
functional heterogeneity in myogenesis even among the muscle precursor cell pool [155]. 
In the present study, we demonstrated that even after in vitro expansion and 
cryopreservation, primary human muscle cell cultures include various subpopulations, as 
indicated by expression of diverse cell lineage markers. Using a modified collection of cell 
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lineage markers: CD45, CD56, CD146, and UEA-1R, we identified and purified to homogeneity 
four distinct cell populations from cryo-hPSMCs, including two stem cell subpopulations: 
pericytes (CD146
+
/CD45
-
CD56
-
UEA-1R
-
) and MECs (CD56
+
CD146
+
UEA-1R
+
/CD45
-
) [26, 45, 
153]. Newly sorted MECs, pericytes, ECs, and Myo cells were immediately transplanted into the 
cardiotoxin-injured skeletal muscles of SCID mice to examine the preservation of their myogenic 
potential after FACS. All of which regenerated human spectrin-positive myofibers in injured 
mouse skeletal muscles. Quantitative analyses using sorted subpopulations that were minimally 
expanded in culture showed that MECs displayed the highest muscle regenerative capacity 
among all cell subsets tested, and pericytes were superior to myoblasts and unpurified cryo-
hPSMCs.  
These results were consistent with our previous observations from injections of cells 
isolated from fresh skeletal muscle biopsies [26, 45]. Taken together, our results suggest the 
presence of distinct subpopulations of highly myogenic stem/progenitor cells within culture-
expanded, cryopreserved hPSMCs and support the feasibility of further purifying stem cell 
fractions from these unpurified cryopreserved human cells. Most importantly, these findings 
infer the practicability of prospective isolation of myogenic stem/progenitor cell populations 
from banked human skeletal muscle cells, highlighting a new technology to further enhance the 
availability and efficacy of cell-mediated therapies [156]. 
5.5 CONCLUSION 
In summary, in this chapter, I demonstrate that MECs isolated from fresh human muscle biopsy 
possess greater myogenic capability than pericytes from the same source. Subpopulations of 
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BVSCs, including MECs and pericytes, can be simultaneously purified by cell sorting from 
cryopreserved human primary skeletal muscle cell cultures (cryo-hPSMCs). MECs isolated from 
cryo-hPSMCs maintained the highest regenerative capacity in the injured mouse muscles among 
all cell fractions tested, while pericytes remained superior to myoblasts and the unpurified 
primary skeletal muscle cells. This study represents a technical breakthrough for simultaneous 
isolation of multiple myogenic BVSC populations, from either fresh muscle biopsies or cryo-
hPSMCs. It is, however, remained to be tested whether MECs and pericytes isolated from cryo-
hPSMCs are functionally and developmentally identical to their freshly isolated counterparts 
from the same muscle biopsy. Due to the limited amount of each muscle biopsy, we were unable 
to obtain sufficient number of unsorted primary muscle cells for both experiments in order to 
perform a side-by-side comparison. 
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6.0  SUMMARY AND FUTURE DIRECTIONS 
Multipotent stem/progenitor cells with similar developmental potentials have been independently 
identified from diverse human tissue/organ cultures. The increasing recognition of the 
vascular/perivascular origin of mesenchymal precursors suggested blood vessels being a 
systemic source of adult stem/progenitor cells. Our group and other laboratories recently isolated 
multiple stem/progenitor cell subsets from blood vessels of adult human tissues. Each of the 
three structural layers of blood vessels: intima, media, and adventitia, has been found to include 
at least one precursor population, i.e. myogenic endothelial cells (MECs), pericytes, and 
adventitial  cells (ACs), respectively. MECs and pericytes efficiently regenerate myofibers in 
injured and dystrophic skeletal muscles. MECs also improve cardiac function after myocardial 
infarction. The applications of ACs in vascular remodeling and angiogenesis/vasculogenesis 
have been examined. These findings suggest that blood vessels play a critical role in tissue repair, 
resulting from the regenerative power of blood-vessel-derived stem cells (BVSCs).  
Despite decades of research, cardiovascular diseases remain the leading cause of 
morbidity and mortality worldwide and a daunting challenge for mankind to overcome. Stem cell 
therapy has gained an increasing attention in the past decade and is deemed promising as the 
future alternatives for tissue/organ transplantation. Multipotent mesodermal precursor cells, 
including mesenchymal stem cells (MSCs) and MSC-like cells, are by far the most accessible 
sources for autologous transplantation. In the cardiovascular milieu, MSCs have been 
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extensively tested for their therapeutic efficacy in pre-clinical and clinical trials, with many 
mechanisms of action being proposed, for example, paracrine secretion of trophic factors, 
regulation of post-injury tissue remodeling, immunoregulation, activation of endogenous 
repair/regeneration mechanisms, vasculogenesis and cardiomyogenesis. Enhancement of MSC 
cellular function and improvement of delivery modality are currently under intensive 
investigation. Nevertheless, the retrospective identification and heterogeneous nature of MSCs in 
culture hindered further research progress. The recent discovery of the likely perivascular origin 
of MSCs represents a new chapter in stem cell research and a giant leap to understand 
pathophysiological roles of mesodermal precursors in the adult human body. BVSC populations, 
including MECs, pericytes, and ACs, are well defined cells subsets that are presumably 
contributing to such a multipotent mesodermal precursor pool. With purified BVSC populations, 
we will be able to harness progresses made with MSCs in order to systematically understand the 
regenerative capacity associated with these precursor cells in each organ. Nonetheless, whether 
there exists a hierarchy between these subsets of BVSCs remains unclear to date. Further 
research is required to investigate their potential relationship, developmentally and functionally, 
as well as the regulation of these multipotent precursors during tissue repair/regeneration. 
Despite microvascular pericytes purified from multiple human organs have been shown 
to possess multipotency and repair/regenerate defective tissues, notably skeletal muscle, their 
ability to repair the ischemic heart remains unknown. In Chapter 3, I have investigated and 
documented the therapeutic potential and associated repair mechanisms of human skeletal 
muscle-derived microvascular pericytes in a murine model of myocardial infarction. Briefly, 
echocardiographic analysis of acutely infarcted mouse myocardium injected with human 
pericytes revealed reduced left ventricular dilatation and significant improvement in cardiac 
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contractility for up to 2 months. Host angiogenesis was significantly increased around and within 
the infarct area. Vascular support by pericytes was illustrated by their perivascular homing in 
vivo and the formation of capillary networks with/without endothelial cells in two- and 3-
dimensional co-cultures. Under hypoxia, pericytes dramatically increased expression of VEGF-A, 
PDGF-β, TGF-β1 and corresponding receptors while expression of bFGF, HGF, EGF, and Ang-
1 was repressed. High expression of MMP-2, but not MMP-9, by pericytes was observed in 
hypoxic cultures. Pericyte treatment substantially reduced myocardial fibrosis and significantly 
diminished infiltration of host inflammatory cells at the infarct site. Furthermore, hypoxic 
pericyte-conditioned medium suppressed fibroblast proliferation and inhibited 
monocyte/macrophage proliferation in vitro. High expression of immunoregulatory molecules by 
pericytes, including IL-6, LIF, COX-2 and HMOX-1, was sustained under hypoxia, except MCP-
1. Finally, GFP-based cell tracking revealed that pericytes differentiate into and/or fuse with 
cardiomyocytes, endothelial and smooth muscle cells, though to a minor extent. These findings 
suggest that intramyocardial transplantation of pericytes post-infarction promotes functional and 
structural recovery, presumably attributable to multiple restorative mechanisms involving 
paracrine effects and cellular interactions.  
Based on the work described in Chapter 3, I am currently extending the research to the 
following directions in order to further understand the regenerative capacity of pericytes in the 
ischemic heart. First, to investigate the significance of donor cell-derived VEGF during pericyte-
mediated cardiac repair, I am using lentiviral anti-VEGF shRNA to block the secretion of VEGF 
from pericytes, in collaboration with Dr. Bing Wang (Department of Orthopedic Surgery, 
University of Pittsburgh). Second, in order to understand the mechanism of anti-inflammatory 
effect by donor pericytes, I am collaborating with Dr. Stephen Badylak (Department of Surgery, 
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University of Pittsburgh) to investigate the immunoregulation during the regenerative response, 
including the regulation of M1/M2 phenotype switching in host macrophages. Finally, it is 
important to investigate the efficacy of treatment with pericytes and/or other BVSC subsets in a 
chronic MI model, which is more clinically relevant.  
It is not clear whether pericytes residing in human heart possess multipotency and 
stem/progenitor cell characteristics similar to their developmentally distinct counterparts in other 
organs. In Chapter 4, I explored the hypothesis that pericytes are present within the human 
myocardium as multi-lineage mesodermal progenitors with tissue specificity. 
Immunohistochemistry showed that human adult and fetal cardiac microvascular pericytes 
express known pericyte markers in situ, including CD146, NG2, PDGFR-β, SMA, and SM-
MHC, but not CD117, CD133, and endothelial cell markers. Human heart cells were isolated 
from ventricular myocardial biopsies by mechanical dissociation and collagenase digestion and 
subsequently subjected to fluorescence-activated cell sorting (FACS) for purification. Using a 
combination of selective cell surface markers, including positive selection marker CD146 and 
negative selection markers: CD34, CD45, CD56, and CD117, we prospectively purified human 
heart pericytes (HPs) to homogeny. Sorted HPs (CD146
+
CD34
-
CD45
-
CD56
-
CD117
-
) can be 
cultured in the long term and displayed morphological and proliferative profiles similar to 
skeletal muscle-derived pericytes (SkMPs). Cultured HPs consistently expressed CD146, NG2, 
SMA, alkaline phosphatase (ALP), and notably PDGFR-. When seeded in Matrigel cultures, 
HPs not only formed capillary-like networks alone but also tightly interact with endothelial cells 
in co-cultures to facilitate angiogenic network formation under ambient and low oxygen 
conditions, showing functional discreteness from SkMPs under hypoxia. HPs natively express 
classic MSC markers, including CD44, CD73, CD90, and CD105 and exhibited robust osteo-, 
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chondro-, and adipogenesis, but not skeletal myogenesis, in culture. No myotube formation or 
expression of fast skeletal myosin heavy chain was observed, suggesting tissue specificity of HPs, 
distinct from pericytes of other origins, in myogenesis.  
Currently we are investigating the differential activation of myogenic genes in HPs after 
induction as well as the engraftment and cardiomyocyte differentiation of transplanted GFP-
labeled HPs within the healthy and ischemic myocardium in immunodeficient mouse models. 
Further investigation of their differentiation into all cardiac cell lineages has been planned. 
Whether there exists a potential hierarchical relationship between heart pericytes and resident c-
kit+ or Isl1+ cardiac stem cells remains unknown. It is also important to investigate the role of 
heart pericytes in supporting resident cardiac stem/progenitor cells. 
To facilitate clinical translation of BVSCs for tissue repair and regeneration, I compared 
the myogenic efficiency of BVSC populations of different lineage, namely MECs and pericytes. 
MECs isolated from fresh human muscle biopsy exhibited the highest myogenic capacity in 
culture. In addition, I demonstrated that populations of BVSCs, such as MECs and pericytes, can 
be simultaneously purified by cell sorting from cryopreserved human primary skeletal muscle 
cell cultures (cryo-hPSMCs), a more clinically accessible cell source. MECs (CD56
+
UEA-
1R
+
CD146
+
/CD45
-
) and pericytes (CD146
+
/CD45
-
CD56
-
UEA-1R
-
) retained their superior 
myogenic capacity in the injured mouse muscles. My findings suggest that long-term 
cryopreserved primary tissue/cell cultures can serve as a source of stem cells in the clinical 
setting. This new approach can be used to readily extract therapeutic stem cells from human 
muscle cells cryogenically banked for clinical purposes.  
Currently I am expanding the research work described in Chapter 5 in to the following 
directions. First, I am investigating the difference(s) in the mechanisms, other than direct 
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myogenesis, which different BVSCs subsets utilize to promote repair/regeneration of the 
damaged skeletal muscle. Second, it is important to evaluate the efficiency of BVSCs subsets 
differentiating into other mesenchymal lineages such as osteogenesis and chondrogenesis. To 
facilitate the translational use of cryo-BVSCs subsets, we have planned to examine their 
repair/regenerative capacity in other animal disease models such as myocardial infarction and 
skull defect models. 
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